[10-Q] ZOETIS INC. Quarterly Earnings Report
Filing Impact
Filing Sentiment
Form Type
10-Q
Zoetis (ZTS) Q2-25 10-Q highlights:
- Revenue rose 4.2% YoY to $2.46 bn; H1-25 up 2.8% to $4.68 bn.
- Net income climbed 15.1% YoY to $718 m; diluted EPS $1.61 vs $1.37. H1 EPS $3.02 (+13%).
- Gross margin improved to 73.6% (cost of sales down 2.8% despite higher volume).
- Operating expenses were mixed: SG&A +6.2%, R&D flat, amortization -6.3%. Restructuring & A&D costs fell to $30 m from $42 m.
- Effective tax rate 20.4% vs 20.0%.
- Segment trends: Companion animal +8.4% to $1.79 bn; Livestock -8.1% to $638 m. Strongest products: Parasiticides (+12%), Vaccines (+13%), Dermatology (+11%). Anti-infectives -17%.
- Cash $1.44 bn (-$552 m YTD) after $781 m buybacks and $447 m dividends. Debt unchanged at $6.65 bn; net debt up.
- Treasury shares outstanding 57.9 m; $4.9 bn remains on $6 bn repurchase authorization.
- Inventory rose 5.8% YoY to $2.44 bn; restructuring accrual $20 m.
- IRS audit could add up to $450 m tax liability; uncertain timing.
Overall, Zoetis delivered double-digit EPS growth driven by companion animal strength and margin expansion, while livestock softness, rising inventories and tax/audit uncertainties warrant monitoring.
Principali dati del 10-Q di Zoetis (ZTS) per il secondo trimestre 2025:
- I ricavi sono aumentati del 4,2% su base annua, raggiungendo 2,46 miliardi di dollari; nel primo semestre 2025 sono cresciuti del 2,8% a 4,68 miliardi di dollari.
- L'utile netto è salito del 15,1% su base annua a 718 milioni di dollari; l'EPS diluito è stato di 1,61 dollari rispetto a 1,37 dollari. L'EPS del primo semestre è stato di 3,02 dollari (+13%).
- Il margine lordo è migliorato al 73,6% (il costo delle vendite è diminuito del 2,8% nonostante l'aumento del volume).
- Le spese operative sono state miste: SG&A +6,2%, R&S stabile, ammortamenti -6,3%. I costi per ristrutturazioni e acquisizioni/disinvestimenti sono scesi a 30 milioni di dollari da 42 milioni.
- L'aliquota fiscale effettiva è stata del 20,4% contro il 20,0% precedente.
- Tendenze per segmento: animali da compagnia +8,4% a 1,79 miliardi; animali da allevamento -8,1% a 638 milioni. Prodotti più forti: antiparassitari (+12%), vaccini (+13%), dermatologia (+11%). Antinfettivi -17%.
- Liquidità pari a 1,44 miliardi di dollari (-552 milioni da inizio anno) dopo riacquisti per 781 milioni e dividendi per 447 milioni. Debito invariato a 6,65 miliardi; indebitamento netto in aumento.
- Azioni proprie in portafoglio 57,9 milioni; rimangono 4,9 miliardi disponibili sull'autorizzazione di riacquisto da 6 miliardi.
- Le scorte sono aumentate del 5,8% su base annua a 2,44 miliardi; accantonamento per ristrutturazione di 20 milioni.
- L'audit IRS potrebbe comportare una passività fiscale fino a 450 milioni; tempistiche incerte.
In generale, Zoetis ha registrato una crescita a doppia cifra dell'EPS grazie alla forza del segmento animali da compagnia e all'espansione dei margini, mentre la debolezza nel settore degli animali da allevamento, l'aumento delle scorte e le incertezze fiscali e di audit richiedono attenzione.
Aspectos destacados del 10-Q del segundo trimestre de 2025 de Zoetis (ZTS):
- Los ingresos aumentaron un 4,2% interanual hasta 2,46 mil millones de dólares; en el primer semestre de 2025 crecieron un 2,8% hasta 4,68 mil millones.
- La utilidad neta subió un 15,1% interanual a 718 millones de dólares; el BPA diluido fue de 1,61 dólares frente a 1,37. El BPA del primer semestre fue de 3,02 (+13%).
- El margen bruto mejoró a 73,6% (el costo de ventas bajó 2,8% a pesar del mayor volumen).
- Los gastos operativos fueron mixtos: SG&A +6,2%, I+D estable, amortización -6,3%. Los costos de reestructuración y adquisiciones/ventas bajaron a 30 millones desde 42 millones.
- La tasa impositiva efectiva fue del 20,4% frente al 20,0% anterior.
- Tendencias por segmento: animales de compañía +8,4% a 1,79 mil millones; ganado -8,1% a 638 millones. Productos más fuertes: parasiticidas (+12%), vacunas (+13%), dermatología (+11%). Anti-infecciosos -17%.
- Cash 1,44 mil millones (-552 millones en lo que va de año) tras recompras por 781 millones y dividendos por 447 millones. Deuda sin cambios en 6,65 mil millones; deuda neta al alza.
- Acciones en tesorería 57,9 millones; quedan 4,9 mil millones disponibles de la autorización de recompra de 6 mil millones.
- Inventarios subieron 5,8% interanual a 2,44 mil millones; provisión por reestructuración de 20 millones.
- La auditoría del IRS podría añadir hasta 450 millones en pasivos fiscales; tiempo incierto.
En conjunto, Zoetis mostró un crecimiento de BPA de dos dígitos impulsado por la fortaleza en animales de compañía y la expansión de márgenes, aunque la debilidad en ganado, el aumento de inventarios y las incertidumbres fiscales y de auditoría merecen seguimiento.
Zoetis (ZTS) 2025년 2분기 10-Q 주요 내용:
- 매출은 전년 동기 대비 4.2% 증가한 24억 6천만 달러를 기록; 2025년 상반기 매출은 2.8% 증가한 46억 8천만 달러.
- 순이익은 전년 동기 대비 15.1% 증가한 7억 1,800만 달러; 희석 주당순이익(EPS)은 1.61달러로 전년 1.37달러 대비 상승. 상반기 EPS는 3.02달러로 13% 증가.
- 매출총이익률은 73.6%로 개선(판매원가 2.8% 감소에도 불구하고 판매량 증가).
- 영업비용은 혼재: 판매관리비(SG&A) +6.2%, 연구개발비(R&D) 변동 없음, 감가상각비 -6.3%. 구조조정 및 인수·매각 비용은 4,200만 달러에서 3,000만 달러로 감소.
- 유효 세율은 20.4%로 전년 20.0% 대비 소폭 상승.
- 사업 부문 동향: 반려동물 부문 8.4% 증가한 17억 9천만 달러; 가축 부문 8.1% 감소한 6억 3,800만 달러. 강세 제품: 기생충 구제제(+12%), 백신(+13%), 피부과 제품(+11%). 항감염제 -17% 감소.
- 현금 14억 4천만 달러(연초 대비 5억 5,200만 달러 감소), 자사주 매입 7억 8,100만 달러, 배당금 4억 4,700만 달러 지급. 부채는 66억 5천만 달러로 변동 없으며 순부채는 증가.
- 자사주 보유량 5,790만 주; 60억 달러 자사주 매입 승인 중 49억 달러 잔액 남음.
- 재고는 전년 대비 5.8% 증가한 24억 4천만 달러; 구조조정 충당금 2,000만 달러.
- IRS 감사로 최대 4억 5천만 달러 세금 부과 가능성; 시기는 불확실.
전반적으로 Zoetis는 반려동물 부문의 강세와 마진 확대에 힘입어 두 자릿수 EPS 성장을 기록했으나, 가축 부문의 부진, 재고 증가 및 세금/감사 관련 불확실성은 주의가 필요하다.
Points clés du 10-Q de Zoetis (ZTS) pour le deuxième trimestre 2025 :
- Le chiffre d'affaires a augmenté de 4,2 % en glissement annuel pour atteindre 2,46 milliards de dollars ; le premier semestre 2025 est en hausse de 2,8 % à 4,68 milliards.
- Le bénéfice net a progressé de 15,1 % en glissement annuel à 718 millions de dollars ; le BPA dilué est de 1,61 $ contre 1,37 $. Le BPA du premier semestre est de 3,02 $ (+13 %).
- La marge brute s'est améliorée à 73,6 % (le coût des ventes a diminué de 2,8 % malgré un volume plus élevé).
- Les charges d'exploitation sont mitigées : SG&A +6,2 %, R&D stable, amortissements -6,3 %. Les coûts de restructuration et d'acquisitions/cessions sont passés de 42 à 30 millions de dollars.
- Le taux d'imposition effectif est de 20,4 % contre 20,0 % auparavant.
- Tendances par segment : animaux de compagnie +8,4 % à 1,79 milliard ; élevage -8,1 % à 638 millions. Produits phares : antiparasitaires (+12 %), vaccins (+13 %), dermatologie (+11 %). Anti-infectieux -17 %.
- Trésorerie de 1,44 milliard (-552 millions depuis le début de l'année) après rachats d'actions pour 781 millions et dividendes de 447 millions. Dette stable à 6,65 milliards ; dette nette en hausse.
- Actions propres en portefeuille 57,9 millions ; 4,9 milliards restent disponibles sur une autorisation de rachat de 6 milliards.
- Les stocks ont augmenté de 5,8 % en glissement annuel à 2,44 milliards ; provision pour restructuration de 20 millions.
- L'audit de l'IRS pourrait entraîner une charge fiscale supplémentaire allant jusqu'à 450 millions ; calendrier incertain.
Dans l'ensemble, Zoetis a affiché une croissance à deux chiffres du BPA portée par la vigueur du segment animaux de compagnie et l'expansion des marges, tandis que la faiblesse dans l'élevage, la hausse des stocks et les incertitudes fiscales et d'audit méritent une surveillance.
Zoetis (ZTS) Q2-25 10-Q Highlights:
- Umsatz stieg im Jahresvergleich um 4,2 % auf 2,46 Mrd. USD; im ersten Halbjahr 2025 um 2,8 % auf 4,68 Mrd. USD.
- Der Nettogewinn kletterte um 15,1 % auf 718 Mio. USD; das verwässerte Ergebnis je Aktie (EPS) betrug 1,61 USD gegenüber 1,37 USD. Das EPS für das erste Halbjahr lag bei 3,02 USD (+13 %).
- Die Bruttomarge verbesserte sich auf 73,6 % (Kosten der verkauften Waren sanken um 2,8 % trotz höherer Absatzmengen).
- Betriebskosten waren gemischt: SG&A +6,2 %, F&E unverändert, Abschreibungen -6,3 %. Restrukturierungs- und Akquisitions-/Veräußerungskosten sanken von 42 Mio. auf 30 Mio. USD.
- Effektiver Steuersatz 20,4 % gegenüber 20,0 %.
- Segmenttrends: Heimtiere +8,4 % auf 1,79 Mrd. USD; Nutztiere -8,1 % auf 638 Mio. USD. Stärkste Produkte: Parasitika (+12 %), Impfstoffe (+13 %), Dermatologie (+11 %). Antiinfektiva -17 %.
- Barmittel 1,44 Mrd. USD (-552 Mio. USD seit Jahresbeginn) nach Aktienrückkäufen von 781 Mio. USD und Dividenden von 447 Mio. USD. Schulden unverändert bei 6,65 Mrd. USD; Nettoverschuldung gestiegen.
- Eigene Aktien im Bestand 57,9 Mio.; 4,9 Mrd. USD verbleiben aus einer Rückkaufgenehmigung von 6 Mrd. USD.
- Inventar stieg um 5,8 % auf 2,44 Mrd. USD; Rückstellung für Restrukturierung 20 Mio. USD.
- IRS-Prüfung könnte bis zu 450 Mio. USD Steuerschuld hinzufügen; Zeitpunkt ungewiss.
Insgesamt erzielte Zoetis ein zweistelliges EPS-Wachstum, getrieben durch die Stärke im Heimtiersegment und Margenausweitung, während die Schwäche im Nutztierbereich, steigende Lagerbestände sowie steuerliche und Prüfungsunsicherheiten beobachtet werden sollten.
Positive
- EPS up 17.5% YoY, outpacing revenue growth, signalling margin expansion.
- Companion animal revenue +8.4% with double-digit gains in parasiticides, vaccines and dermatology.
- Gross margin +190 bp aided by lower cost of sales and product mix.
- $781 m share repurchases and $447 m dividends demonstrate strong capital return capacity.
- Restructuring costs down vs prior year, indicating progress on efficiency initiatives.
Negative
- Livestock revenue -8.1%, reflecting cattle, swine and poultry softness.
- Cash balance fell $552 m YTD, partly due to aggressive buybacks.
- Inventory rose 5.8%, potentially tying up working capital.
- IRS audit could trigger up to $450 m additional tax liability.
- Anti-infectives sales -17%, signalling competitive or demand pressures.
Insights
TL;DR: Solid beat on earnings and margin, cash outflows driven by buybacks; livestock weakness a drag.
Revenue exceeded typical mid-single-digit street expectations, and EPS grew ~18%, implying continued pricing and mix leverage in companion animal lines. Gross margin gain of ~190 bp shows successful cost discipline and divestiture of low-margin medicated feed additives. Shareholder returns remain aggressive—$1.2 bn YTD (dividends + repurchases)—pushing net leverage to ~1.6× EBITDA but still comfortable given 73% gross margin and $1 bn unused revolver. Key watch-items are: 1) livestock decline which now represents only 26% of sales but is sensitive to commodity cycles; 2) inventory build that could pressure future working capital; 3) pending IRS case that could create a one-off hit up to $0.90/share. Management’s shift toward external manufacturing and site closure should add to margin tailwinds once restructuring completes.
TL;DR: Companion animal demand, especially parasiticides & dermatology, remains robust; livestock slump reflects cyclical end-markets.
Double-digit growth in parasiticides and dermatology underlines enduring pet care spend despite macro noise. Vaccines also re-accelerated, aided by aquaculture and poultry recovery. Livestock weakness was broad—cattle, swine and poultry all down—mirroring producer margin compression; this is cyclical rather than structural. Divestiture of medicated feed additives removes a volatile, lower-growth line and simplifies portfolio. Competitive positioning vs Elanco & Boehringer remains strong given R&D throughput and diagnostics expansion. Longer-term catalysts include monoclonal antibodies for canine osteoarthritis and point-of-care diagnostics, which are insulated from generic pressure. Overall industry fundamentals stay favorable, making Zoetis’ results strategically positive.
Principali dati del 10-Q di Zoetis (ZTS) per il secondo trimestre 2025:
- I ricavi sono aumentati del 4,2% su base annua, raggiungendo 2,46 miliardi di dollari; nel primo semestre 2025 sono cresciuti del 2,8% a 4,68 miliardi di dollari.
- L'utile netto è salito del 15,1% su base annua a 718 milioni di dollari; l'EPS diluito è stato di 1,61 dollari rispetto a 1,37 dollari. L'EPS del primo semestre è stato di 3,02 dollari (+13%).
- Il margine lordo è migliorato al 73,6% (il costo delle vendite è diminuito del 2,8% nonostante l'aumento del volume).
- Le spese operative sono state miste: SG&A +6,2%, R&S stabile, ammortamenti -6,3%. I costi per ristrutturazioni e acquisizioni/disinvestimenti sono scesi a 30 milioni di dollari da 42 milioni.
- L'aliquota fiscale effettiva è stata del 20,4% contro il 20,0% precedente.
- Tendenze per segmento: animali da compagnia +8,4% a 1,79 miliardi; animali da allevamento -8,1% a 638 milioni. Prodotti più forti: antiparassitari (+12%), vaccini (+13%), dermatologia (+11%). Antinfettivi -17%.
- Liquidità pari a 1,44 miliardi di dollari (-552 milioni da inizio anno) dopo riacquisti per 781 milioni e dividendi per 447 milioni. Debito invariato a 6,65 miliardi; indebitamento netto in aumento.
- Azioni proprie in portafoglio 57,9 milioni; rimangono 4,9 miliardi disponibili sull'autorizzazione di riacquisto da 6 miliardi.
- Le scorte sono aumentate del 5,8% su base annua a 2,44 miliardi; accantonamento per ristrutturazione di 20 milioni.
- L'audit IRS potrebbe comportare una passività fiscale fino a 450 milioni; tempistiche incerte.
In generale, Zoetis ha registrato una crescita a doppia cifra dell'EPS grazie alla forza del segmento animali da compagnia e all'espansione dei margini, mentre la debolezza nel settore degli animali da allevamento, l'aumento delle scorte e le incertezze fiscali e di audit richiedono attenzione.
Aspectos destacados del 10-Q del segundo trimestre de 2025 de Zoetis (ZTS):
- Los ingresos aumentaron un 4,2% interanual hasta 2,46 mil millones de dólares; en el primer semestre de 2025 crecieron un 2,8% hasta 4,68 mil millones.
- La utilidad neta subió un 15,1% interanual a 718 millones de dólares; el BPA diluido fue de 1,61 dólares frente a 1,37. El BPA del primer semestre fue de 3,02 (+13%).
- El margen bruto mejoró a 73,6% (el costo de ventas bajó 2,8% a pesar del mayor volumen).
- Los gastos operativos fueron mixtos: SG&A +6,2%, I+D estable, amortización -6,3%. Los costos de reestructuración y adquisiciones/ventas bajaron a 30 millones desde 42 millones.
- La tasa impositiva efectiva fue del 20,4% frente al 20,0% anterior.
- Tendencias por segmento: animales de compañía +8,4% a 1,79 mil millones; ganado -8,1% a 638 millones. Productos más fuertes: parasiticidas (+12%), vacunas (+13%), dermatología (+11%). Anti-infecciosos -17%.
- Cash 1,44 mil millones (-552 millones en lo que va de año) tras recompras por 781 millones y dividendos por 447 millones. Deuda sin cambios en 6,65 mil millones; deuda neta al alza.
- Acciones en tesorería 57,9 millones; quedan 4,9 mil millones disponibles de la autorización de recompra de 6 mil millones.
- Inventarios subieron 5,8% interanual a 2,44 mil millones; provisión por reestructuración de 20 millones.
- La auditoría del IRS podría añadir hasta 450 millones en pasivos fiscales; tiempo incierto.
En conjunto, Zoetis mostró un crecimiento de BPA de dos dígitos impulsado por la fortaleza en animales de compañía y la expansión de márgenes, aunque la debilidad en ganado, el aumento de inventarios y las incertidumbres fiscales y de auditoría merecen seguimiento.
Zoetis (ZTS) 2025년 2분기 10-Q 주요 내용:
- 매출은 전년 동기 대비 4.2% 증가한 24억 6천만 달러를 기록; 2025년 상반기 매출은 2.8% 증가한 46억 8천만 달러.
- 순이익은 전년 동기 대비 15.1% 증가한 7억 1,800만 달러; 희석 주당순이익(EPS)은 1.61달러로 전년 1.37달러 대비 상승. 상반기 EPS는 3.02달러로 13% 증가.
- 매출총이익률은 73.6%로 개선(판매원가 2.8% 감소에도 불구하고 판매량 증가).
- 영업비용은 혼재: 판매관리비(SG&A) +6.2%, 연구개발비(R&D) 변동 없음, 감가상각비 -6.3%. 구조조정 및 인수·매각 비용은 4,200만 달러에서 3,000만 달러로 감소.
- 유효 세율은 20.4%로 전년 20.0% 대비 소폭 상승.
- 사업 부문 동향: 반려동물 부문 8.4% 증가한 17억 9천만 달러; 가축 부문 8.1% 감소한 6억 3,800만 달러. 강세 제품: 기생충 구제제(+12%), 백신(+13%), 피부과 제품(+11%). 항감염제 -17% 감소.
- 현금 14억 4천만 달러(연초 대비 5억 5,200만 달러 감소), 자사주 매입 7억 8,100만 달러, 배당금 4억 4,700만 달러 지급. 부채는 66억 5천만 달러로 변동 없으며 순부채는 증가.
- 자사주 보유량 5,790만 주; 60억 달러 자사주 매입 승인 중 49억 달러 잔액 남음.
- 재고는 전년 대비 5.8% 증가한 24억 4천만 달러; 구조조정 충당금 2,000만 달러.
- IRS 감사로 최대 4억 5천만 달러 세금 부과 가능성; 시기는 불확실.
전반적으로 Zoetis는 반려동물 부문의 강세와 마진 확대에 힘입어 두 자릿수 EPS 성장을 기록했으나, 가축 부문의 부진, 재고 증가 및 세금/감사 관련 불확실성은 주의가 필요하다.
Points clés du 10-Q de Zoetis (ZTS) pour le deuxième trimestre 2025 :
- Le chiffre d'affaires a augmenté de 4,2 % en glissement annuel pour atteindre 2,46 milliards de dollars ; le premier semestre 2025 est en hausse de 2,8 % à 4,68 milliards.
- Le bénéfice net a progressé de 15,1 % en glissement annuel à 718 millions de dollars ; le BPA dilué est de 1,61 $ contre 1,37 $. Le BPA du premier semestre est de 3,02 $ (+13 %).
- La marge brute s'est améliorée à 73,6 % (le coût des ventes a diminué de 2,8 % malgré un volume plus élevé).
- Les charges d'exploitation sont mitigées : SG&A +6,2 %, R&D stable, amortissements -6,3 %. Les coûts de restructuration et d'acquisitions/cessions sont passés de 42 à 30 millions de dollars.
- Le taux d'imposition effectif est de 20,4 % contre 20,0 % auparavant.
- Tendances par segment : animaux de compagnie +8,4 % à 1,79 milliard ; élevage -8,1 % à 638 millions. Produits phares : antiparasitaires (+12 %), vaccins (+13 %), dermatologie (+11 %). Anti-infectieux -17 %.
- Trésorerie de 1,44 milliard (-552 millions depuis le début de l'année) après rachats d'actions pour 781 millions et dividendes de 447 millions. Dette stable à 6,65 milliards ; dette nette en hausse.
- Actions propres en portefeuille 57,9 millions ; 4,9 milliards restent disponibles sur une autorisation de rachat de 6 milliards.
- Les stocks ont augmenté de 5,8 % en glissement annuel à 2,44 milliards ; provision pour restructuration de 20 millions.
- L'audit de l'IRS pourrait entraîner une charge fiscale supplémentaire allant jusqu'à 450 millions ; calendrier incertain.
Dans l'ensemble, Zoetis a affiché une croissance à deux chiffres du BPA portée par la vigueur du segment animaux de compagnie et l'expansion des marges, tandis que la faiblesse dans l'élevage, la hausse des stocks et les incertitudes fiscales et d'audit méritent une surveillance.
Zoetis (ZTS) Q2-25 10-Q Highlights:
- Umsatz stieg im Jahresvergleich um 4,2 % auf 2,46 Mrd. USD; im ersten Halbjahr 2025 um 2,8 % auf 4,68 Mrd. USD.
- Der Nettogewinn kletterte um 15,1 % auf 718 Mio. USD; das verwässerte Ergebnis je Aktie (EPS) betrug 1,61 USD gegenüber 1,37 USD. Das EPS für das erste Halbjahr lag bei 3,02 USD (+13 %).
- Die Bruttomarge verbesserte sich auf 73,6 % (Kosten der verkauften Waren sanken um 2,8 % trotz höherer Absatzmengen).
- Betriebskosten waren gemischt: SG&A +6,2 %, F&E unverändert, Abschreibungen -6,3 %. Restrukturierungs- und Akquisitions-/Veräußerungskosten sanken von 42 Mio. auf 30 Mio. USD.
- Effektiver Steuersatz 20,4 % gegenüber 20,0 %.
- Segmenttrends: Heimtiere +8,4 % auf 1,79 Mrd. USD; Nutztiere -8,1 % auf 638 Mio. USD. Stärkste Produkte: Parasitika (+12 %), Impfstoffe (+13 %), Dermatologie (+11 %). Antiinfektiva -17 %.
- Barmittel 1,44 Mrd. USD (-552 Mio. USD seit Jahresbeginn) nach Aktienrückkäufen von 781 Mio. USD und Dividenden von 447 Mio. USD. Schulden unverändert bei 6,65 Mrd. USD; Nettoverschuldung gestiegen.
- Eigene Aktien im Bestand 57,9 Mio.; 4,9 Mrd. USD verbleiben aus einer Rückkaufgenehmigung von 6 Mrd. USD.
- Inventar stieg um 5,8 % auf 2,44 Mrd. USD; Rückstellung für Restrukturierung 20 Mio. USD.
- IRS-Prüfung könnte bis zu 450 Mio. USD Steuerschuld hinzufügen; Zeitpunkt ungewiss.
Insgesamt erzielte Zoetis ein zweistelliges EPS-Wachstum, getrieben durch die Stärke im Heimtiersegment und Margenausweitung, während die Schwäche im Nutztierbereich, steigende Lagerbestände sowie steuerliche und Prüfungsunsicherheiten beobachtet werden sollten.
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |||||
| For the quarterly period ended | |||||
or | |||||
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |||||
| For the transition period from __________ to __________ | |||||
| Commission File Number: | |||||
| (Exact name of registrant as specified in its charter) | ||
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |||||||||||||
| (Address of principal executive offices) | (Zip Code) | |||||||||||||
(973 ) 822-7000
(Registrant’s telephone number, including area code) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
| ☒ | Accelerated filer | ☐ | Non-accelerated filer | ☐ | Smaller reporting company | Emerging growth company | |||||||||||||||||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No
As of August 1, 2025, there were 443,183,472 shares of common stock outstanding.
Table of Contents
TABLE OF CONTENTS
| Page | ||||||||||||||
PART I — FINANCIAL INFORMATION | 1 | |||||||||||||
| Item 1. | Financial Statements | 1 | ||||||||||||
| Condensed Consolidated Statements of Income (Unaudited) | 1 | |||||||||||||
| Condensed Consolidated Statements of Comprehensive Income (Unaudited) | 2 | |||||||||||||
| Condensed Consolidated Balance Sheets (Unaudited) | 3 | |||||||||||||
| Condensed Consolidated Statements of Equity (Unaudited) | 4 | |||||||||||||
| Condensed Consolidated Statements of Cash Flows (Unaudited) | 6 | |||||||||||||
| Notes to Condensed Consolidated Financial Statements (Unaudited) | 7 | |||||||||||||
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 21 | ||||||||||||
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 38 | ||||||||||||
| Item 4. | Controls and Procedures | 39 | ||||||||||||
PART II — OTHER INFORMATION | 40 | |||||||||||||
| Item 1. | Legal Proceedings | 40 | ||||||||||||
| Item 1A. | Risk Factors | 40 | ||||||||||||
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 42 | ||||||||||||
| Item 3. | Defaults Upon Senior Securities | 42 | ||||||||||||
| Item 4. | Mine Safety Disclosures | 42 | ||||||||||||
| Item 5. | Other Information | 42 | ||||||||||||
| Item 6. | Exhibits | 43 | ||||||||||||
SIGNATURES | 44 | |||||||||||||
Table of Contents
PART I – FINANCIAL INFORMATION
Item 1. Financial Statements
ZOETIS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||
| June 30, | June 30, | |||||||||||||||||||||||||
| (MILLIONS OF DOLLARS AND SHARES, EXCEPT PER SHARE DATA) | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||||
| Revenue | $ | $ | $ | $ | ||||||||||||||||||||||
| Costs and expenses: | ||||||||||||||||||||||||||
Cost of sales | ||||||||||||||||||||||||||
Selling, general and administrative expenses | ||||||||||||||||||||||||||
Research and development expenses | ||||||||||||||||||||||||||
Amortization of intangible assets | ||||||||||||||||||||||||||
| Restructuring charges and certain acquisition and divestiture-related costs | ||||||||||||||||||||||||||
Interest expense, net of capitalized interest | ||||||||||||||||||||||||||
Other (income)/deductions—net | ( | |||||||||||||||||||||||||
| Income before provision for taxes on income | ||||||||||||||||||||||||||
| Provision for taxes on income | ||||||||||||||||||||||||||
| Net income before allocation to noncontrolling interests | ||||||||||||||||||||||||||
| Less: Net income/(loss) attributable to noncontrolling interests | ||||||||||||||||||||||||||
| Net income attributable to Zoetis Inc. | $ | $ | $ | $ | ||||||||||||||||||||||
| Earnings per share attributable to Zoetis Inc. stockholders: | ||||||||||||||||||||||||||
| Basic | $ | $ | $ | $ | ||||||||||||||||||||||
| Diluted | $ | $ | $ | $ | ||||||||||||||||||||||
| Weighted-average common shares outstanding: | ||||||||||||||||||||||||||
| Basic | ||||||||||||||||||||||||||
| Diluted | ||||||||||||||||||||||||||
| Dividends declared per common share | $ | $ | $ | $ | ||||||||||||||||||||||
See notes to condensed consolidated financial statements.
1 |
Table of Contents
ZOETIS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||
| June 30, | June 30, | |||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||||
| Net income before allocation to noncontrolling interests | $ | $ | $ | $ | ||||||||||||||||||||||
Other comprehensive income/(loss), net of tax(a): | ||||||||||||||||||||||||||
Unrealized losses on derivatives for cash flow hedges, net of tax of $( | ( | ( | ( | ( | ||||||||||||||||||||||
Unrealized (losses)/gains on derivatives for net investment hedges, net of tax of $( | ( | ( | ||||||||||||||||||||||||
| Foreign currency translation adjustments | ( | ( | ||||||||||||||||||||||||
| Total other comprehensive income/(loss), net of tax | ( | ( | ||||||||||||||||||||||||
| Comprehensive income before allocation to noncontrolling interests | ||||||||||||||||||||||||||
| Less: Comprehensive income/(loss) attributable to noncontrolling interests | ||||||||||||||||||||||||||
| Comprehensive income attributable to Zoetis Inc. | $ | $ | $ | $ | ||||||||||||||||||||||
(a) Presented net of reclassification adjustments, which are not material in any period presented.
See notes to condensed consolidated financial statements.
2 |
Table of Contents
ZOETIS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
| June 30, | December 31, | |||||||||||||
| 2025 | 2024 | |||||||||||||
| (MILLIONS OF DOLLARS, EXCEPT SHARE AND PER SHARE DATA) | (Unaudited) | |||||||||||||
| Assets | ||||||||||||||
Cash and cash equivalents(a) | $ | $ | ||||||||||||
Accounts receivable, less allowance for doubtful accounts of $ | ||||||||||||||
| Inventories | ||||||||||||||
| Other current assets | ||||||||||||||
| Total current assets | ||||||||||||||
Property, plant and equipment, less accumulated depreciation of $ | ||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||
| Goodwill | ||||||||||||||
| Identifiable intangible assets, less accumulated amortization | ||||||||||||||
| Noncurrent deferred tax assets | ||||||||||||||
| Other noncurrent assets | ||||||||||||||
| Total assets | $ | $ | ||||||||||||
| Liabilities and Equity | ||||||||||||||
| Current portion of long-term debt | $ | $ | ||||||||||||
| Accounts payable | ||||||||||||||
| Dividends payable | ||||||||||||||
| Accrued expenses | ||||||||||||||
| Accrued compensation and related items | ||||||||||||||
| Income taxes payable | ||||||||||||||
| Other current liabilities | ||||||||||||||
| Total current liabilities | ||||||||||||||
| Long-term debt, net of discount and issuance costs | ||||||||||||||
| Noncurrent deferred tax liabilities | ||||||||||||||
| Operating lease liabilities | ||||||||||||||
| Other taxes payable | ||||||||||||||
| Other noncurrent liabilities | ||||||||||||||
| Total liabilities | ||||||||||||||
| Commitments and contingencies (Note 15) | ||||||||||||||
Stockholders’ equity: | ||||||||||||||
Common stock, $ | ||||||||||||||
Treasury stock, at cost, | ( | ( | ||||||||||||
| Additional paid-in capital | ||||||||||||||
| Retained earnings | ||||||||||||||
| Accumulated other comprehensive loss | ( | ( | ||||||||||||
| Total Zoetis Inc. equity | ||||||||||||||
| Equity attributable to noncontrolling interests | ||||||||||||||
| Total equity | ||||||||||||||
| Total liabilities and equity | $ | $ | ||||||||||||
(a) As of June 30, 2025 and December 31, 2024, includes $0 million and $2 million of restricted cash, respectively.
See notes to condensed consolidated financial statements.
3 |
Table of Contents
ZOETIS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(UNAUDITED)
| Three months ended June 30, 2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Zoetis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accumulated | Equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Additional | Other | Attributable to | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Common Stock | Treasury Stock | Paid-in | Retained | Comprehensive | Noncontrolling | Total | ||||||||||||||||||||||||||||||||||||||||||||||||||
(MILLIONS OF DOLLARS AND SHARES) | Shares | Amount | Shares | Amount | Capital | Earnings | Loss | Interests | Equity | |||||||||||||||||||||||||||||||||||||||||||||||
| Balance, March 31, 2025 | $ | $ | ( | $ | $ | $ | ( | $ | $ | |||||||||||||||||||||||||||||||||||||||||||||||
| Net income | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive income | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||
Share-based compensation awards (a) | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Treasury stock acquired (b) | — | — | ( | — | — | — | — | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
| Dividends declared | — | — | — | — | — | ( | — | — | ( | |||||||||||||||||||||||||||||||||||||||||||||||
| Balance, June 30, 2025 | $ | $ | ( | $ | $ | $ | ( | $ | $ | |||||||||||||||||||||||||||||||||||||||||||||||
| Three months ended June 30, 2024 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Zoetis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accumulated | Equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Additional | Other | Attributable to | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Common Stock | Treasury Stock | Paid-in | Retained | Comprehensive | Noncontrolling | Total | ||||||||||||||||||||||||||||||||||||||||||||||||||
(MILLIONS OF DOLLARS AND SHARES) | Shares | Amount | Shares | Amount | Capital | Earnings | Loss | Interests | Equity | |||||||||||||||||||||||||||||||||||||||||||||||
| Balance, March 31, 2024 | $ | $ | ( | $ | $ | $ | ( | $ | ( | $ | ||||||||||||||||||||||||||||||||||||||||||||||
| Net income | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive loss | — | — | — | — | — | — | ( | — | ( | |||||||||||||||||||||||||||||||||||||||||||||||
Share-based compensation awards (a) | — | — | ( | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||
Treasury stock acquired (b) | — | — | ( | — | — | — | — | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
| Dividends declared | — | — | — | — | — | ( | — | — | ( | |||||||||||||||||||||||||||||||||||||||||||||||
| Balance, June 30, 2024 | $ | $ | ( | $ | $ | $ | ( | $ | ( | $ | ||||||||||||||||||||||||||||||||||||||||||||||
Shares may not add due to rounding.
(a) Includes the issuance of shares of Zoetis Inc. common stock and the reacquisition of shares of treasury stock associated with exercises of employee share-based awards. Also includes the reacquisition of shares of treasury stock associated with the vesting of employee share-based awards to satisfy tax withholding requirements. For additional information, see Note 12. Share-based Payments and Note 13. Stockholders’ Equity.
(b) Reflects the acquisition of treasury shares in connection with the share repurchase program and includes excise tax accrued on net share repurchases. For additional information, see Note 13. Stockholders’ Equity.
See notes to condensed consolidated financial statements.
4 |
Table of Contents
ZOETIS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(UNAUDITED) - Continued
| Six months ended June 30, 2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Zoetis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accumulated | Equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Additional | Other | Attributable to | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Common Stock | Treasury Stock | Paid-in | Retained | Comprehensive | Noncontrolling | Total | ||||||||||||||||||||||||||||||||||||||||||||||||||
(MILLIONS OF DOLLARS AND SHARES) | Shares | Amount | Shares | Amount | Capital | Earnings | Loss | Interests | Equity | |||||||||||||||||||||||||||||||||||||||||||||||
| Balance, December 31, 2024 | $ | $ | ( | $ | $ | $ | ( | $ | $ | |||||||||||||||||||||||||||||||||||||||||||||||
| Net income | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive income | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||
Share-based compensation awards (a) | — | — | ( | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||
Treasury stock acquired (b) | — | — | ( | — | — | — | — | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
| Dividends declared | — | — | — | — | — | ( | — | — | ( | |||||||||||||||||||||||||||||||||||||||||||||||
| Balance, June 30, 2025 | $ | $ | ( | $ | $ | $ | ( | $ | $ | |||||||||||||||||||||||||||||||||||||||||||||||
| Six months ended June 30, 2024 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Zoetis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accumulated | Equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Additional | Other | Attributable to | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Common Stock | Treasury Stock | Paid-in | Retained | Comprehensive | Noncontrolling | Total | ||||||||||||||||||||||||||||||||||||||||||||||||||
(MILLIONS OF DOLLARS AND SHARES) | Shares | Amount | Shares | Amount | Capital | Earnings | Loss | Interests | Equity | |||||||||||||||||||||||||||||||||||||||||||||||
| Balance, December 31, 2023 | $ | $ | ( | $ | $ | $ | ( | $ | ( | $ | ||||||||||||||||||||||||||||||||||||||||||||||
| Net income | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive loss | — | — | — | — | — | — | ( | — | ( | |||||||||||||||||||||||||||||||||||||||||||||||
Share-based compensation awards (a) | — | — | ( | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||
Treasury stock acquired (b) | — | — | ( | — | — | — | — | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
| Dividends declared | — | — | — | — | — | ( | — | — | ( | |||||||||||||||||||||||||||||||||||||||||||||||
| Balance, June 30, 2024 | $ | $ | ( | $ | $ | $ | ( | $ | ( | $ | ||||||||||||||||||||||||||||||||||||||||||||||
Shares may not add due to rounding.
(a) Includes the issuance of shares of Zoetis Inc. common stock and the reacquisition of shares of treasury stock associated with exercises of employee share-based awards. Also includes the reacquisition of shares of treasury stock associated with the vesting of employee share-based awards to satisfy tax withholding requirements. For additional information, see Note 12. Share-based Payments and Note 13. Stockholders’ Equity.
(b) Reflects the acquisition of treasury shares in connection with the share repurchase program and includes excise tax accrued on net share repurchases. For additional information, see Note 13. Stockholders’ Equity.
See notes to condensed consolidated financial statements.
5 |
Table of Contents
ZOETIS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
| Six Months Ended | ||||||||||||||
| June 30, | ||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | ||||||||||||
| Operating Activities | ||||||||||||||
| Net income before allocation to noncontrolling interests | $ | $ | ||||||||||||
| Adjustments to reconcile net income before noncontrolling interests to net cash provided by operating activities: | ||||||||||||||
| Depreciation and amortization expense | ||||||||||||||
| Share-based compensation expense | ||||||||||||||
| Asset write-offs and asset impairments | ||||||||||||||
| Net loss on sale of business, excluding transaction costs | ||||||||||||||
| Provision for losses on inventory | ||||||||||||||
| Deferred taxes | ( | |||||||||||||
| Other non-cash adjustments | ( | |||||||||||||
| Other changes in assets and liabilities, net of acquisitions and divestitures: | ||||||||||||||
| Accounts receivable | ( | ( | ||||||||||||
| Inventories | ( | ( | ||||||||||||
| Other assets | ( | ( | ||||||||||||
| Accounts payable | ||||||||||||||
| Other liabilities | ( | ( | ||||||||||||
| Other tax accounts, net | ( | ( | ||||||||||||
| Net cash provided by operating activities | ||||||||||||||
| Investing Activities | ||||||||||||||
| Capital expenditures | ( | ( | ||||||||||||
| Acquisitions, net of cash acquired | ( | ( | ||||||||||||
| Purchase of investments | ( | ( | ||||||||||||
| (Payments of)/proceeds from derivative instrument activity, net | ( | |||||||||||||
| Proceeds from sale of business, net of cash sold and working capital adjustments | ( | |||||||||||||
| Net proceeds from sale of assets | ||||||||||||||
| Other investing activities | ( | ( | ||||||||||||
| Net cash used in investing activities | ( | ( | ||||||||||||
| Financing Activities | ||||||||||||||
| Decrease in short-term borrowings, net | ( | |||||||||||||
| Payment of consideration related to previous acquisitions | ( | |||||||||||||
| Share-based compensation-related proceeds, net of taxes paid on withholding shares | ( | ( | ||||||||||||
| Purchases of treasury stock, including excise taxes paid | ( | ( | ||||||||||||
| Cash dividends paid | ( | ( | ||||||||||||
| Other financing activities | ( | |||||||||||||
| Net cash used in financing activities | ( | ( | ||||||||||||
| Effect of exchange-rate changes on cash and cash equivalents | ( | |||||||||||||
| Net decrease in cash and cash equivalents | ( | ( | ||||||||||||
| Cash and cash equivalents at beginning of period | ||||||||||||||
| Cash and cash equivalents at end of period | $ | $ | ||||||||||||
| Supplemental cash flow information | ||||||||||||||
| Cash paid during the period for: | ||||||||||||||
Income taxes(a) | $ | $ | ||||||||||||
| Interest, net of capitalized interest | ||||||||||||||
| Amounts included in the measurement of lease liabilities: | ||||||||||||||
| Operating cash flows - operating leases | ||||||||||||||
| Financing cash flows - finance leases | ||||||||||||||
| Non-cash transactions: | ||||||||||||||
| Capital expenditures | ||||||||||||||
| Excise tax accrued on net share repurchases, not paid | ||||||||||||||
| Lease obligations obtained in exchange for right-of-use assets - operating | ||||||||||||||
| Lease obligations obtained in exchange for right-of-use assets - finance | ||||||||||||||
| Dividends declared, not paid | ||||||||||||||
(a) For the six months ended June 30, 2025, includes $88 million related to the purchase of transferable federal tax credits.
See notes to condensed consolidated financial statements.
6 |
Table of Contents
ZOETIS INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
1. Organization
Zoetis Inc. (including its subsidiaries, collectively, Zoetis, the company, we, us or our) is a global leader in the animal health industry, focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. We organize and operate our business in two geographic regions: the United States (U.S.) and International.
We directly market our products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. Our products are sold in more than 100 countries, including developed and emerging markets. We have a diversified business, marketing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock); and within seven major product categories: parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical and animal health diagnostics. On October 31, 2024, we completed the divestiture of our medicated feed additive product portfolio, certain water soluble products and related assets, and, as a result, our major product categories no longer include the category of medicated feed additives. See Note 5. Divestitures.
2. Basis of Presentation
The accompanying unaudited condensed consolidated financial statements were prepared following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three and six months ended May 31, 2025 and 2024.
Revenue, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
Certain reclassifications of prior year information have been made to conform to the current year presentation.
In the third quarter of 2024, we concluded that we were no longer the primary beneficiary of a variable interest entity (VIE) that was previously consolidated. The effects of the deconsolidation were not material to the condensed consolidated financial statements.
3. Accounting Standards
Recently Adopted Accounting Standards
In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The new guidance requires standardized categories for the effective tax rate reconciliation, disaggregation of income taxes paid and other income tax-related disclosures. This update is effective for fiscal years beginning after December 15, 2024. We adopted this guidance as of January 1, 2025, which will result in additional disclosures in the notes to our annual consolidated financial statements.
Recently Issued Accounting Standards
In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The new guidance requires a public business entity to provide disaggregated disclosures, in the notes to the financial statements, of certain categories of expenses that are included in expense line items on the face of the income statement. The amendments in this Update are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. We are currently evaluating the impact that the new guidance will have on our notes to the condensed consolidated financial statements.
4. Revenue
A. Revenue from Product Sales
We offer a diversified portfolio of products which allows us to capitalize on local and regional customer needs. Generally, our products are promoted to veterinarians and livestock producers by our sales organization which includes sales representatives and technical and veterinary operations specialists, and then sold directly by us or through distributors, retailers or e-commerce outlets. The depth of our product portfolio enables us to address the varying needs of customers in different species and geographies. Many of our top-selling product lines are distributed across both of our operating segments, leveraging our research and development (R&D) operations and manufacturing and supply chain network.
Over the course of our history, we have focused on developing a diverse portfolio of animal health products, including medicines, vaccines and diagnostics, complemented by biodevices, genetic tests and a range of services. We refer to all different brands of a particular product, or its dosage forms for all species, as a product line. We have approximately 300 comprehensive product lines, including products for both companion animals and livestock, within each of our major product categories.
On October 31, 2024, we completed the divestiture of our medicated feed additive product portfolio, certain water soluble products and related assets,
7 |
Table of Contents
and, as a result, our major product categories no longer include the category of medicated feed additives. See Note 5. Divestitures.
Our major product categories are:
•parasiticides: products that prevent or eliminate external and internal parasites such as fleas, ticks, lice and worms;
•vaccines: biological preparations that help prevent diseases of the respiratory, gastrointestinal and reproductive tracts or induce a specific immune response;
•dermatology: products that relieve itch associated with allergic conditions and atopic dermatitis;
•anti-infectives: products that prevent, kill or slow the growth of bacteria, fungi or protozoa;
•pain and sedation: products that alleviate pain, primarily associated with osteoarthritis and postoperative pain;
•other pharmaceutical: antiemetic, reproductive and oncology products; and
•animal health diagnostics: testing and analysis of blood, urine and other animal samples and related products and services, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services and blood glucose monitors.
Our remaining revenue is derived from other non-pharmaceutical product categories, such as nutritionals, as well as products and services in biodevices, genetic tests and precision animal health.
Our companion animal products help extend and improve the quality of life for pets; increase convenience and compliance for pet owners; and help veterinarians improve the quality of their care and the efficiency of their businesses. Growth in the companion animal medicines, vaccines and diagnostics sector is driven by economic development, related increases in disposable income and increases in pet ownership and spending on pet care. Companion animals are also living longer, deepening the human-animal bond, receiving increased medical treatment and benefiting from advances in animal health medicine, vaccines and diagnostics.
Our livestock products primarily help prevent or treat diseases and conditions to allow veterinarians and producers to care for their animals and to enable the cost-effective production of safe, high-quality animal protein. Human population growth and increasing standards of living are important long-term growth drivers for our livestock products in three major ways. First, population growth and increasing standards of living drive demand for improved nutrition, particularly through increased consumption of animal protein. Second, population growth leads to greater natural resource constraints driving a need for enhanced productivity. Finally, as standards of living improve and the global food chain faces increased scrutiny, there is more focus on food quality, safety and reliability of supply.
The following tables present our revenue disaggregated by geographic area, species and major product category:
Revenue by geographic area
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||
| June 30, | June 30, | |||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||||
| United States | $ | $ | $ | $ | ||||||||||||||||||||||
| Australia | ||||||||||||||||||||||||||
| Brazil | ||||||||||||||||||||||||||
| Canada | ||||||||||||||||||||||||||
| Chile | ||||||||||||||||||||||||||
| China | ||||||||||||||||||||||||||
| France | ||||||||||||||||||||||||||
| Germany | ||||||||||||||||||||||||||
| Italy | ||||||||||||||||||||||||||
| Japan | ||||||||||||||||||||||||||
| Mexico | ||||||||||||||||||||||||||
| Spain | ||||||||||||||||||||||||||
| United Kingdom | ||||||||||||||||||||||||||
| Other developed markets | ||||||||||||||||||||||||||
| Other emerging markets | ||||||||||||||||||||||||||
| Contract manufacturing & human health | ||||||||||||||||||||||||||
| Total Revenue | $ | $ | $ | $ | ||||||||||||||||||||||
8 |
Table of Contents
Revenue by major species
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||
| June 30, | June 30, | |||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||||
| U.S. | ||||||||||||||||||||||||||
| Companion animal | $ | $ | $ | $ | ||||||||||||||||||||||
| Livestock | ||||||||||||||||||||||||||
| International | ||||||||||||||||||||||||||
| Companion animal | ||||||||||||||||||||||||||
| Livestock | ||||||||||||||||||||||||||
| Total | ||||||||||||||||||||||||||
| Companion animal | ||||||||||||||||||||||||||
| Livestock | ||||||||||||||||||||||||||
| Contract manufacturing & human health | ||||||||||||||||||||||||||
| Total Revenue | $ | $ | $ | $ | ||||||||||||||||||||||
Revenue by species
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||
| June 30, | June 30, | |||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||||
| Companion Animal: | ||||||||||||||||||||||||||
| Dogs and Cats | $ | $ | $ | $ | ||||||||||||||||||||||
| Horses | ||||||||||||||||||||||||||
| Livestock: | ||||||||||||||||||||||||||
| Cattle | ||||||||||||||||||||||||||
| Swine | ||||||||||||||||||||||||||
| Poultry | ||||||||||||||||||||||||||
| Fish | ||||||||||||||||||||||||||
| Sheep and other | ||||||||||||||||||||||||||
| Contract manufacturing & human health | ||||||||||||||||||||||||||
| Total Revenue | $ | $ | $ | $ | ||||||||||||||||||||||
Revenue by major product category
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||
| June 30, | June 30, | |||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||||
| Parasiticides | $ | $ | $ | $ | ||||||||||||||||||||||
| Vaccines | ||||||||||||||||||||||||||
| Dermatology | ||||||||||||||||||||||||||
| Anti-infectives | ||||||||||||||||||||||||||
| Pain and sedation | ||||||||||||||||||||||||||
| Other pharmaceutical | ||||||||||||||||||||||||||
| Animal health diagnostics | ||||||||||||||||||||||||||
| Other non-pharmaceutical | ||||||||||||||||||||||||||
| Medicated feed additives | ||||||||||||||||||||||||||
| Contract manufacturing & human health | ||||||||||||||||||||||||||
| Total Revenue | $ | $ | $ | $ | ||||||||||||||||||||||
B. Revenue from Contracts with Customers
Contract liabilities reflected within Other current liabilities as of December 31, 2024 and 2023, and subsequently recognized as revenue during each of the first six months of 2025 and 2024 were $5 million and $3 million, respectively. Contract liabilities as of June 30, 2025 and December 31, 2024 were $19 million and $18 million, respectively.
9 |
Table of Contents
5. Divestitures
6. Restructuring Charges and Other Costs Associated with Acquisitions and Divestitures
In connection with our cost-reduction/productivity initiatives, we typically incur restructuring charges associated with workforce reductions and site closings. In connection with our acquisition and divestiture activities, we typically incur costs associated with executing the transactions. Acquisition activity may also include integrating the acquired operations, which may include expenditures for consulting and the integration of systems and processes, product transfers and restructuring the company, which may include charges related to employees, assets and activities that will not continue in the company. Divestiture activity may also include costs to separate the divested operations, which may include expenditures for consulting and the disintegration of systems and processes, transfer costs, and restructuring charges which may include charges related to employees, assets and activities that will not continue in the company's ongoing operations. All operating functions can be impacted by these actions, including sales and marketing, manufacturing and R&D, as well as functions such as business technology, shared services and corporate operations.
The components of costs incurred in connection with restructuring initiatives, acquisitions and divestitures are as follows:
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||
| June 30, | June 30, | |||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||||
| Restructuring charges and certain acquisition and divestiture-related costs: | ||||||||||||||||||||||||||
| Acquisition-related costs | $ | $ | $ | $ | ||||||||||||||||||||||
| Divestiture-related costs | ||||||||||||||||||||||||||
Restructuring charges, net(a): | ||||||||||||||||||||||||||
| Employee termination costs, net | $ | $ | ||||||||||||||||||||||||
| Asset impairment charges | ||||||||||||||||||||||||||
| Exit costs | ||||||||||||||||||||||||||
Total Restructuring charges and certain acquisition and divestiture-related costs | $ | $ | $ | $ | ||||||||||||||||||||||
(a) Restructuring charges for the three and six months ended June 30, 2025 primarily consisted of asset impairment charges and employee termination costs related to a transition from internal to external innovation and manufacturing of certain products and the closure of a related site.
Restructuring charges for the three and six months ended June 30, 2024 primarily consisted of employee termination costs related to organizational structure refinements. Restructuring charges for the six months ended June 30, 2024 were partially offset by a reversal of certain employee termination costs as a result of a change in strategy from our 2015 operational efficiency initiative.
The change in our restructuring accrual is as follows:
| (MILLIONS OF DOLLARS) | Accrual | |||||||||||||||||||||||||||||||
Balance, December 31, 2024(a) | $ | |||||||||||||||||||||||||||||||
| Provision | ||||||||||||||||||||||||||||||||
| Non-cash activity | ( | |||||||||||||||||||||||||||||||
Utilization and other(b) | ( | |||||||||||||||||||||||||||||||
Balance, June 30, 2025(a) | $ | |||||||||||||||||||||||||||||||
(a) At June 30, 2025 and December 31, 2024, included in Accrued expenses ($18 million and $26 million, respectively) and Other noncurrent liabilities ($2 million).
7. Other (Income)/Deductions—Net
The components of Other (income)/deductions—net are as follows:
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||
| June 30, | June 30, | |||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||||
| Interest income | $ | ( | $ | ( | $ | ( | $ | ( | ||||||||||||||||||
Identifiable intangible asset impairment charges(a) | ||||||||||||||||||||||||||
Net loss on sale of business(b) | ||||||||||||||||||||||||||
Foreign currency loss(c) | ||||||||||||||||||||||||||
| Other, net | ( | ( | ||||||||||||||||||||||||
| Other (income)/deductions—net | $ | $ | $ | ( | $ | |||||||||||||||||||||
(a) For the three and six months ended June 30, 2025 and 2024, represents asset impairment charges related to our aquaculture product portfolio.
(b) Represents a net loss related to the sale of our medicated feed additive product portfolio, certain water soluble products and related assets sold in 2024. For additional information, see Note 5. Divestitures.
(c) Primarily driven by costs related to hedging and exposures to certain emerging and developed market currencies.
10 |
Table of Contents
8. Income Taxes
A. Taxes on Income
Our effective tax rate was 20.4 % and 20.0 % for the three months ended June 30, 2025 and 2024, respectively, and 21.2 % and 19.9 % for the six months ended June 30, 2025 and 2024, respectively. The higher effective tax rate for the three and six months ended June 30, 2025, compared with the three and six months ended June 30, 2024, was primarily attributable to a lower benefit in the U.S. related to foreign-derived intangible income, higher net discrete tax expenses, partially offset by a more favorable jurisdictional mix of earnings (which includes the impact of the location of pre-tax earnings, tax impact of permanent differences and repatriation decisions).
In 2024, the company implemented an initiative to maximize its cash position in the U.S. This initiative resulted in a tax benefit in the U.S. in connection with a prepayment from a related foreign entity in Belgium which qualifies as foreign-derived intangible income; however, this income tax benefit was deferred to 2025 and 2026. A portion of this benefit was recognized during the three and six months ended June 30, 2025.
B. Deferred Taxes
As of June 30, 2025, the total net deferred income tax asset of $461 million is included in Noncurrent deferred tax assets ($617 million) and Noncurrent deferred tax liabilities ($156 million).
As of December 31, 2024, the total net deferred income tax asset of $373 million is included in Noncurrent deferred tax assets ($540 million) and Noncurrent deferred tax liabilities ($167 million).
C. Tax Contingencies
Uncertain Tax Positions
As of June 30, 2025, the net tax liabilities associated with uncertain tax positions of $219 million (exclusive of interest and penalties related to uncertain tax positions of $45 million) are included in Other taxes payable.
As of December 31, 2024, the net tax liabilities associated with uncertain tax positions of $213 million (exclusive of interest and penalties related to uncertain tax positions of $38 million) are included in Other taxes payable.
Our tax liabilities for uncertain tax positions relate primarily to issues common among multinational corporations. Any settlements or statute of limitations expirations could result in a significant decrease in our uncertain tax positions. Substantially all of these unrecognized tax benefits, if recognized, would impact our effective income tax rate. We do not expect that within the next twelve months any of our uncertain tax positions could significantly decrease as a result of settlements with taxing authorities or the expiration of the statutes of limitations. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of uncertain tax positions and potential tax benefits may not be representative of actual outcomes, and any variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant.
Status of Tax Audits and Potential Impact on Accrual for Uncertain Tax Positions
We are currently under income tax audit by the U.S. Internal Revenue Service (IRS) for tax years 2017 and 2018. In July 2024, the IRS issued Notices of Proposed Adjustment (NOPA) related to the one-time mandatory deemed repatriation tax incurred on the 2018 U.S. Federal Income Tax return. In September 2024, the IRS issued a Revenue Agent Report (RAR) for the adjustments identified in the NOPA and a protest was filed with the IRS on November 15, 2024. As of June 30, 2025, the additional tax liability, based on the income adjustment proposed by the IRS under the RAR, is approximately $450 million, excluding interest and penalties.
9. Financial Instruments
A. Debt
Credit Facilities
In December 2022, we entered into an amended and restated revolving credit agreement with a syndicate of banks providing for a multi-year $1.0 billion senior unsecured revolving credit facility (the credit facility), which expires in December 2027. Subject to certain conditions, we have the right to increase the credit facility to up to $1.5 billion. The credit facility contains a financial covenant requiring us to not exceed a maximum total leverage ratio (the ratio of consolidated net debt as of the end of the period to consolidated Earnings Before Interest, Income Taxes, Depreciation and Amortization (EBITDA) for such period) of 3.50 :1. Upon entering into a material acquisition, the maximum total leverage ratio increases to 4.00 :1, and extends until the fourth full consecutive fiscal quarter ended immediately following the consummation of a material acquisition. In addition, the credit facility contains other customary covenants.
We were in compliance with all financial covenants as of June 30, 2025 and December 31, 2024. There were no
We have additional lines of credit and other credit arrangements with a group of banks and other financial intermediaries for general corporate purposes. We maintain cash and cash equivalent balances in excess of our outstanding short-term borrowings. As of June 30, 2025, we had access to
11 |
Table of Contents
$53 million of lines of credit which expire at various times and are generally renewed annually. There were no borrowings outstanding related to these facilities as of June 30, 2025 and December 31, 2024.
Commercial Paper Program
In February 2013, we entered into a commercial paper program with a capacity of up to $1.0 billion. As of June 30, 2025 and December 31, 2024, there was no
Senior Notes and Other Long-Term Debt
Our senior notes are governed by an indenture and supplemental indentures (collectively, the indenture) between us and Deutsche Bank Trust Company Americas, as trustee. The indenture contains certain covenants, including limitations on our and certain of our subsidiaries’ ability to incur liens or engage in sale-leaseback transactions. The indenture also contains restrictions on our ability to consolidate, merge or sell substantially all of our assets. In addition, the indenture contains other customary terms, including certain events of default, upon the occurrence of which the senior notes may be declared immediately due and payable.
Pursuant to the indenture, we are able to redeem the senior notes of any series, in whole or in part, at any time by paying a “make whole” premium, plus accrued and unpaid interest to, but excluding, the date of redemption. Upon the occurrence of a change of control of us and a downgrade of the senior notes below an investment grade rating by each of Moody’s Investors Service, Inc. and Standard & Poor’s Ratings Services, we are, in certain circumstances, required to make an offer to repurchase all of the outstanding senior notes at a price equal to 101 % of the aggregate principal amount of the senior notes together with accrued and unpaid interest to, but excluding, the date of repurchase.
The components of our long-term debt are as follows:
| June 30, | December 31, | |||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | ||||||||||||
| $ | $ | |||||||||||||
| Unamortized debt discount / debt issuance costs | ( | ( | ||||||||||||
| Less current portion of long-term debt | ||||||||||||||
| Cumulative fair value adjustment for interest rate swap contracts | ( | ( | ||||||||||||
| Long-term debt, net of discount and issuance costs | $ | $ | ||||||||||||
The fair value of our long-term debt was $6,229 million and $6,097 million as of June 30, 2025 and December 31, 2024, respectively, and has been determined using a third-party model that uses significant inputs derived from, or corroborated by, observable market data, including benchmark security prices and Zoetis’ credit spreads (Level 2 inputs).
The following table provides the principal amount of debt outstanding, as of June 30, 2025, by scheduled maturity date:
| After | ||||||||||||||||||||||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2026 | 2027 | 2028 | 2029 | 2029 | Total | |||||||||||||||||||||||||||||||||||||
| Maturities | $ | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||||||||||||
Interest Expense
Interest expense, net of capitalized interest, was $53 million and $107 million for the three and six months ended June 30, 2025, respectively, and $59 million and $117 million for the three and six months ended June 30, 2024, respectively. Capitalized interest expense was $11 million and $22 million for the three and six months ended June 30, 2025, respectively, and $9 million and $17 million for the three and six months ended June 30, 2024, respectively.
B. Derivative Financial Instruments
Foreign Exchange Risk
A significant portion of our revenue, earnings and net investment in foreign affiliates is exposed to changes in foreign exchange rates. We seek to manage our foreign exchange risk, in part, through operational means, including managing same-currency revenue in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. Depending on market conditions, foreign exchange risk is also managed through the use of various derivative financial instruments. These derivative financial instruments serve to manage the exposure of our net investment in certain foreign operations to changes in foreign exchange rates and protect net income against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.
All derivative financial instruments used to manage foreign currency risk are measured at fair value and are reported as assets or liabilities on the
12 |
Table of Contents
Condensed Consolidated Balance Sheets. The derivative financial instruments primarily offset exposures in the Australian dollar, British pound, Canadian dollar, Chinese renminbi, euro and Norwegian krone. Changes in fair value are reported in earnings or in Accumulated other comprehensive loss, depending on the nature and purpose of the financial instrument, as follows:
•For foreign currency forward-exchange contracts not designated as hedging instruments, we recognize the gains and losses that are used to offset the same foreign currency assets or liabilities immediately into earnings along with the earnings impact of the items they generally offset. These contracts essentially take the opposite currency position of that reflected in the month-end balance sheet to counterbalance the effect of any currency movement. The vast majority of the foreign currency forward-exchange contracts mature within 60 days and all mature within three years .
•For foreign exchange derivative instruments that are designated as hedging instruments against our net investment in foreign operations, changes in the fair value are recorded as a component of cumulative translation adjustment within Accumulated other comprehensive loss and reclassified into earnings when the foreign investment is sold or substantially liquidated. These instruments include cross-currency interest rate swaps and foreign currency forward-exchange contracts. Gains and losses excluded from the assessment of hedge effectiveness are recognized in earnings (Interest expense, net of capitalized interest). The cash flows from these contracts are reflected within the investing section of our Condensed Consolidated Statements of Cash Flows. These contracts have varying maturities of up to three years .
Interest Rate Risk
The company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rates and to reduce its overall cost of borrowing.
•In anticipation of issuing fixed-rate debt, we may use forward-starting interest rate swaps that are designated as cash flow hedges to hedge against changes in interest rates that could impact expected future issuances of debt. Unrealized gains or losses on the forward-starting interest rate swaps are reported in Accumulated other comprehensive loss and are recognized in earnings over the life of the future fixed rate notes. When the company discontinues hedge accounting because it is no longer probable that an anticipated transaction will occur within the originally expected period of execution, or within an additional two-month period thereafter, changes to fair value accumulated in other comprehensive income are recognized immediately in earnings.
•During the period from 2019 to 2022, we entered into forward-starting interest rate swaps with an aggregate notional value of $650 million. We designated these swaps as cash flow hedges against interest rate exposure related principally to the issuance of fixed-rate debt to refinance our 3.250 % 2013 senior notes due 2023. Upon issuance of our 2022 senior notes, we terminated these contracts and received $114 million in cash from the counterparties for settlement. The settlement amount, which represented the fair value of the contracts at the time of termination, was recorded in Accumulated other comprehensive loss, and will be amortized into income (offset to Interest expense, net of capitalized interest) over the life of the 5.600 % 2022 senior notes due 2032.
•As of June 30, 2025, we had outstanding forward-starting interest rate swaps, having an effective date and mandatory termination date in March 2026, to hedge against interest rate exposure related principally to the anticipated future issuance of fixed-rate debt to be used primarily to refinance our 4.500 % 2015 senior notes due 2025.
•We may use fixed-to-floating interest rate swaps that are designated as fair value hedges to hedge against changes in the fair value of certain fixed-rate debt attributable to changes in the benchmark of the Secured Overnight Financing Rate (SOFR). These derivative instruments effectively convert a portion of the company’s long-term debt from fixed-rate to floating-rate debt based on the daily SOFR rate plus a spread. Gains or losses on the fixed-to-floating interest rate swaps due to changes in SOFR are recorded in Interest expense, net of capitalized interest. Changes in the fair value of the fixed-to-floating interest rate swaps are offset by changes in the fair value of the underlying fixed-rate debt. As of June 30, 2025, we had outstanding fixed-to-floating interest rate swaps that correspond to a portion of the 3.900 % 2018 senior notes due 2028 and the 2.000 % 2020 senior notes due 2030. The amounts recorded during the three and six months ended June 30, 2025 for changes in the fair value of these hedges are not material to our condensed consolidated financial statements.
Outstanding Positions
The aggregate notional amount of derivative instruments are as follows:
| Notional | ||||||||||||||
| June 30, | December 31, | |||||||||||||
| (MILLIONS) | 2025 | 2024 | ||||||||||||
| Derivatives not Designated as Hedging Instruments: | ||||||||||||||
| Foreign currency forward-exchange contracts | $ | $ | ||||||||||||
| Derivatives Designated as Hedging Instruments: | ||||||||||||||
| Foreign exchange derivative instruments (in foreign currency): | ||||||||||||||
| Euro | ||||||||||||||
| Danish krone | ||||||||||||||
| Swiss franc | ||||||||||||||
| Forward-starting interest rate swaps | $ | $ | ||||||||||||
| Fixed-to-floating interest rate swap contracts | $ | $ | ||||||||||||
13 |
Table of Contents
Fair Value of Derivative Instruments
The classification and fair values of derivative instruments are as follows:
| Fair Value of Derivatives | ||||||||||||||
| June 30, | December 31, | |||||||||||||
| (MILLIONS OF DOLLARS) | Balance Sheet Location | 2025 | 2024 | |||||||||||
| Derivatives Not Designated as Hedging Instruments: | ||||||||||||||
| Foreign currency forward-exchange contracts | Other current assets | $ | $ | |||||||||||
| Foreign currency forward-exchange contracts | Other current liabilities | ( | ( | |||||||||||
| Total derivatives not designated as hedging instruments | $ | ( | $ | |||||||||||
| Derivatives Designated as Hedging Instruments: | ||||||||||||||
| Forward-starting interest rate swap contracts | Other current assets | $ | $ | |||||||||||
| Forward-starting interest rate swap contracts | Other noncurrent assets | |||||||||||||
| Forward-starting interest rate swap contracts | Other current liabilities | ( | ||||||||||||
| Foreign exchange derivative instruments | Other current assets | |||||||||||||
| Foreign exchange derivative instruments | Other noncurrent assets | |||||||||||||
| Foreign exchange derivative instruments | Other current liabilities | ( | ||||||||||||
| Foreign exchange derivative instruments | Other noncurrent liabilities | ( | ||||||||||||
| Fixed-to-floating interest rate swap contracts | Other noncurrent liabilities | ( | ( | |||||||||||
| Total derivatives designated as hedging instruments | ( | |||||||||||||
| Total derivatives | $ | ( | $ | |||||||||||
The company’s derivative transactions are subject to master netting agreements that mitigate credit risk by permitting net settlement of transactions with the same counterparty. The company also has collateral security agreements with certain of its counterparties. Under these collateral security agreements each party is required to post cash collateral when the net fair value of derivative instruments covered by the collateral agreement exceeds contractually established thresholds. At June 30, 2025, there was $5 million of collateral received and $64 million of collateral posted related to derivative instruments recorded in Other current liabilities and Other current assets, respectively. At December 31, 2024, there was $51 million of collateral received and $20 million of collateral posted related to derivative instruments recorded in Other current liabilities and Other current assets, respectively.
We use a market approach in valuing financial instruments on a recurring basis. Our derivative financial instruments are measured at fair value on a recurring basis using Level 2 inputs in the calculation of fair value.
The amounts of net gains on derivative instruments not designated as hedging instruments, recorded in Other (income)/deductions—net, are as follows:
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||
| June 30, | June 30, | |||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||||
| Foreign currency forward-exchange contracts | $ | $ | $ | $ | ||||||||||||||||||||||
These amounts were substantially offset in Other (income)/deductions—net by the effect of changing exchange rates on the underlying foreign currency exposures.
The amounts of unrecognized net (losses)/gains on interest rate swap contracts, recorded, net of tax, in Accumulated other comprehensive loss, are as follows:
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||
| June 30, | June 30, | |||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||||
| Forward-starting interest rate swap contracts | $ | ( | $ | $ | ( | $ | ||||||||||||||||||||
| Foreign exchange derivative instruments | $ | ( | $ | $ | ( | $ | ||||||||||||||||||||
Gains on interest rate swap contracts, recognized within Interest expense, net of capitalized interest, are as follows:
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||
| June 30, | June 30, | |||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||||
| Foreign exchange derivative instruments | $ | $ | $ | $ | ||||||||||||||||||||||
The net amount of deferred gains related to derivative instruments designated as cash flow hedges that is expected to be reclassified from Accumulated other comprehensive loss into earnings over the next 12 months is not material.
14 |
Table of Contents
10. Inventories
The components of inventory are as follows:
| June 30, | December 31, | |||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | ||||||||||||
| Finished goods | $ | $ | ||||||||||||
| Work-in-process | ||||||||||||||
| Raw materials and supplies | ||||||||||||||
| Inventories | $ | $ | ||||||||||||
11. Goodwill and Other Intangible Assets
A. Goodwill
The components of, and changes in, the carrying amount of goodwill are as follows:
| (MILLIONS OF DOLLARS) | U.S. | International | Total | |||||||||||||||||
| Balance, December 31, 2024 | $ | $ | $ | |||||||||||||||||
Other(a) | ||||||||||||||||||||
| Balance, June 30, 2025 | $ | $ | $ | |||||||||||||||||
(a) Includes adjustments for foreign currency translation.
The gross goodwill balance was $3,294 million and $3,260 million as of June 30, 2025 and December 31, 2024, respectively. Accumulated goodwill impairment losses were $536
B. Other Intangible Assets
The components of identifiable intangible assets are as follows:
| As of June 30, 2025 | As of December 31, 2024 | |||||||||||||||||||||||||||||||||||||
| Identifiable | Identifiable | |||||||||||||||||||||||||||||||||||||
| Gross | Intangible Assets | Gross | Intangible Assets | |||||||||||||||||||||||||||||||||||
| Carrying | Accumulated | Less Accumulated | Carrying | Accumulated | Less Accumulated | |||||||||||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | Amount | Amortization | Amortization | Amount | Amortization | Amortization | ||||||||||||||||||||||||||||||||
| Finite-lived intangible assets: | ||||||||||||||||||||||||||||||||||||||
| Developed technology rights | $ | $ | ( | $ | $ | $ | ( | $ | ||||||||||||||||||||||||||||||
| Brands and tradenames | ( | ( | ||||||||||||||||||||||||||||||||||||
| Other | ( | ( | ||||||||||||||||||||||||||||||||||||
| Total finite-lived intangible assets | ( | ( | ||||||||||||||||||||||||||||||||||||
| Indefinite-lived intangible assets: | ||||||||||||||||||||||||||||||||||||||
| Brands and tradenames | — | — | ||||||||||||||||||||||||||||||||||||
| In-process research and development | — | — | ||||||||||||||||||||||||||||||||||||
| Product rights | — | — | ||||||||||||||||||||||||||||||||||||
| Total indefinite-lived intangible assets | — | — | ||||||||||||||||||||||||||||||||||||
| Identifiable intangible assets | $ | $ | ( | $ | $ | $ | ( | $ | ||||||||||||||||||||||||||||||
C. Amortization
Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in Amortization of intangible assets as it benefits multiple business functions. Amortization expense related to finite-lived acquired intangible assets that are associated with a single function is included in Cost of sales, Selling, general and administrative expenses or Research and development expenses, as appropriate. Total amortization expense for finite-lived intangible assets was $41 million and $80 million three and six months ended June 30, 2025, respectively and $42 million and $86 million for the three and six months ended June 30, 2024, respectively.
12. Share-based Payments
The Zoetis 2013 Equity and Incentive Plan, Amended and Restated as of May 19, 2022 (Equity Plan), provides long-term incentives to our employees and non-employee directors. The principal types of share-based awards available under the Equity Plan may include, but are not limited to, stock options, restricted stock and restricted stock units (RSUs), deferred stock units (DSUs), performance-vesting restricted stock units (PSUs) and other equity-based or cash-based awards.
15 |
Table of Contents
The components of share-based compensation expense are as follows:
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||
| June 30, | June 30, | |||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||||
| Stock options / stock appreciation rights | $ | $ | $ | $ | ||||||||||||||||||||||
| RSUs / DSUs | ||||||||||||||||||||||||||
| PSUs | ||||||||||||||||||||||||||
Share-based compensation expense—total(a) | $ | $ | $ | $ | ||||||||||||||||||||||
(a) For the three and six months ended June 30, 2025 and 2024, we capitalized less than $1 .
During the six months ended June 30, 2025, the company granted 320,498 stock options with a weighted-average exercise price of $156.80 per stock option and a weighted-average fair value of $40.22 per stock option. The fair-value based method for valuing each Zoetis stock option grant on the grant date uses the Black-Scholes-Merton option-pricing model, which incorporates a number of valuation assumptions. The weighted-average fair value was estimated based on the following assumptions: risk-free interest rate of 4.38 %; expected dividend yield of 1.27 %; expected stock price volatility of 26.42 %; and expected term of 4.3 years. Stock options granted prior to 2023 generally vest after three years of continuous service from the date of grant and have a contractual term of 10 years. Beginning in 2023, stock options granted are subject to graded vesting over three years from the date of grant and have a contractual term of 10 years. The values determined through this fair-value based method generally are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, general and administrative expenses, or Research and development expenses, as appropriate.
During the six months ended June 30, 2025, the company granted 570,063 RSUs with a weighted-average grant date fair value of $156.87 per RSU. RSUs are accounted for using a fair-value-based method that utilizes the closing price of Zoetis common stock on the date of grant. RSUs granted prior to 2023 generally vest after three years of continuous service from the date of grant. Beginning in 2023, RSUs granted are subject to graded vesting over three years from the date of grant. The values generally are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, general and administrative expenses, or Research and development expenses, as appropriate.
During the six months ended June 30, 2025, the company granted 148,130 PSUs with a weighted-average grant date fair value of $171.21 per PSU. Beginning in 2025, the units underlying the PSUs will be earned and vested over a three-year performance period in two tranches, each subject to an independent achievement condition: (1) a market condition comprising the total shareholder return of the company in comparison to the total shareholder return of the companies comprising the S&P 500 Health Care index at the start of the performance period, excluding companies that during the performance period are acquired or no longer publicly traded (Relative TSR); and (2) a performance condition comprising a three-year average annual operational revenue growth metric (average PSU operational revenue growth). PSUs that are earned and vested based upon a market condition are accounted for at fair-value using a Monte Carlo simulation model and PSUs that are earned and vested based upon a performance condition are accounted for at fair-value using the closing price of Zoetis common stock on the date of grant. The Monte Carlo weighted-average fair value was estimated based on volatility assumptions of Zoetis common stock and an average of the S&P 500 Health Care index companies, which were 27.6 % and 29.8 %, respectively. Depending on the company’s Relative TSR performance and the average PSU operational revenue growth at the end of the performance period, the recipient may earn from 0 % to 200 % of the target number of units. Vested units are settled in shares of the company’s common stock. PSU values are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, general and administrative expenses, or Research and development expenses, as appropriate. PSU amortization for units that are earned and vested based upon the average PSU operational revenue growth is adjusted for subsequent changes in the expected outcome of the performance-related condition.
13. Stockholders’ Equity
Zoetis is authorized to issue 6 billion shares of common stock and 1 billion shares of preferred stock.
In August 2024, our Board of Directors authorized a multi-year share repurchase program of up to $6 billion of our outstanding common stock. As of June 30, 2025, there was $4.9 billion remaining under this authorization. Purchases of Zoetis shares may be made at the discretion of management, depending on market conditions and business needs.
Accumulated other comprehensive loss
Changes, net of tax, in accumulated other comprehensive loss, excluding noncontrolling interests were as follows:
| Currency Translation Adjustments | ||||||||||||||||||||||||||||||||
| Other Currency | Benefit Plans | Accumulated Other | ||||||||||||||||||||||||||||||
| Cash Flow | Net Investment | Translation | Actuarial | Comprehensive | ||||||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | Hedges | Hedges | Adjustments | Gains | Loss | |||||||||||||||||||||||||||
| Balance, December 31, 2024 | $ | $ | $ | ( | $ | $ | ( | |||||||||||||||||||||||||
| Other comprehensive (loss)/income, net of tax | ( | ( | ||||||||||||||||||||||||||||||
| Balance, June 30, 2025 | $ | $ | ( | $ | ( | $ | $ | ( | ||||||||||||||||||||||||
| Balance, December 31, 2023 | $ | $ | $ | ( | $ | $ | ( | |||||||||||||||||||||||||
| Other comprehensive (loss)/income, net of tax | ( | ( | ( | |||||||||||||||||||||||||||||
| Balance, June 30, 2024 | $ | $ | $ | ( | $ | $ | ( | |||||||||||||||||||||||||
16 |
Table of Contents
14. Earnings per Share
The following table presents the calculation of basic and diluted earnings per share:
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||
| (MILLIONS OF DOLLARS AND SHARES, EXCEPT PER SHARE DATA) | June 30, | June 30, | ||||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||||||
| Numerator | ||||||||||||||||||||||||||
| Net income before allocation to noncontrolling interests | $ | $ | $ | $ | ||||||||||||||||||||||
| Less: Net income/(loss) attributable to noncontrolling interests | ||||||||||||||||||||||||||
| Net income attributable to Zoetis Inc. | $ | $ | $ | $ | ||||||||||||||||||||||
| Denominator | ||||||||||||||||||||||||||
| Weighted-average common shares outstanding | ||||||||||||||||||||||||||
| Common stock equivalents: stock options, RSUs, PSUs and DSUs | ||||||||||||||||||||||||||
| Weighted-average common and potential dilutive shares outstanding | ||||||||||||||||||||||||||
| Earnings per share attributable to Zoetis Inc. stockholders—basic | $ | $ | $ | $ | ||||||||||||||||||||||
| Earnings per share attributable to Zoetis Inc. stockholders—diluted | $ | $ | $ | $ | ||||||||||||||||||||||
The number of stock options outstanding under the company’s Equity Plan that were excluded from the computation of diluted earnings per share, as the effect would have been antidilutive, were not material for the three and six months ended June 30, 2025 and 2024.
15. Commitments and Contingencies
We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business. For a discussion of our tax contingencies, see Note 8. Income Taxes.
A. Legal Proceedings
Our non-tax contingencies include, among others, the following:
• Product liability and other product-related litigation, which can include injury, consumer, off-label promotion, antitrust and breach of contract claims.
• Commercial and other matters, which can include product-pricing claims and environmental claims and proceedings.
• Patent litigation, which typically involves challenges to the coverage and/or validity of our patents or those of third parties on various products or processes.
• Government investigations, which can involve regulation by national, state and local government agencies in the U.S. and in other countries.
Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, and/or criminal charges, which could be substantial.
We believe that we have strong defenses in these types of matters, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations or cash flows in the period in which the amounts are paid.
We have accrued for losses that are both probable and reasonably estimable. Substantially all of these contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.
Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely on estimates and assumptions.
Ulianopolis, Brazil
In February 2012, the Municipality of Ulianopolis (State of Para, Brazil) filed a complaint against Fort Dodge Saúde Animal Ltda. (FDSAL), a Zoetis entity, and five other large companies alleging that waste sent to a local waste incineration facility for destruction, but that was not ultimately destroyed as the facility lost its operating permit, caused environmental impacts requiring cleanup.
17 |
Table of Contents
The Municipality is seeking recovery of cleanup costs purportedly related to FDSAL’s share of all waste accumulated at the incineration facility awaiting destruction, and compensatory damages to be allocated among the six defendants. We believe we have strong arguments against the claim, including defense strategies against any claim of joint and several liability.
At the request of the Municipal prosecutor, in April 2012, the lawsuit was suspended for one year . Since that time, the prosecutor has initiated investigations into the Municipality's actions in the matter as well as the efforts undertaken by the six defendants to remove and dispose of their individual waste from the incineration facility. On October 3, 2014, the Municipal prosecutor announced that the investigation remained ongoing and outlined the terms of a proposed Term of Reference (a document that establishes the minimum elements to be addressed in the preparation of an Environmental Impact Assessment), under which the companies would be liable to withdraw the waste and remediate the area.
On March 5, 2015, we presented our response to the prosecutor’s proposed Term of Reference, arguing that the proposed terms were overly general in nature and expressing our interest in discussing alternatives to address the matter. The prosecutor agreed to consider our request to engage a technical consultant to conduct an environmental diagnostic of the contaminated area. On May 29, 2015, we, in conjunction with the other defendant companies, submitted a draft cooperation agreement to the prosecutor, which outlined the proposed terms and conditions for the engagement of a technical consultant to conduct the environmental diagnostic. On August 19, 2016, the parties and the prosecutor agreed to engage the services of a third-party consultant to conduct a limited environmental assessment of the site. The site assessment was conducted during June 2017, and a written report summarizing the results of the assessment was provided to the parties and the prosecutor in November 2017. The report noted that waste is still present on the site and that further (Phase II) environmental assessments are needed before a plan to manage that remaining waste can be prepared. On April 1, 2019, the defendants met with the Prosecutor to discuss the conclusions set forth in the written report. Following that discussion, on April 10, 2019, the Prosecutor issued a procedural order requesting that the defendants prepare and submit a technical proposal outlining the steps needed to conduct the additional Phase II environmental assessments. The defendants presented the technical proposal to the Prosecutor on October 21, 2019. On March 3, 2020, the Prosecutor notified the defendants that he submitted the proposal to the Ministry of the Environment for its review and consideration by the Prosecutor. On July 15, 2020, the Prosecutor recommended certain amendments to the proposal for the Phase II testing. On September 28, 2020, the parties and the Prosecutor agreed to the final terms and conditions concerning the cooperation agreement with respect to the Phase II testing. Phase II testing began the week of October 14, 2024. To date, the work has yet to be competed. We expect a report to be issued by the consultant upon conclusion of the testing.
B. Guarantees and Indemnifications
16. Segment Information
Operating Segments
We manage our operations through two geographic regions. Each operating segment has responsibility for its commercial activities. Within each of these operating segments, we offer a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical and animal health diagnostics for both companion animal and livestock customers.
On October 31, 2024, we completed the divestiture of our medicated feed additive product portfolio, certain water soluble products and related assets, and, as a result, our major product categories no longer include the category of medicated feed additives. See Note 5. Divestitures.
Our operating segments are the U.S. and International. The chief operating decision maker (CODM), our Chief Executive Officer and Chief Financial Officer, uses the information provided to compare segment performance with segment resource requests and allocates human and capital resources based on segment’s actual results and expected future results.
Other Costs and Business Activities
Certain costs are not allocated to our operating segment results, such as costs associated with the following:
• Other business activities, includes our Client Supply Services contract manufacturing results, our human health business, and expenses associated with our dedicated veterinary medicine research and development organization, research alliances, U.S. regulatory affairs and other operations focused on the development of our products. Other R&D-related costs associated with non-U.S. market and regulatory activities are generally included in the international commercial segment.
• Corporate, includes enabling functions such as information technology, facilities, legal, finance, human resources, business development, certain diagnostic costs and communications, among others. These costs also include certain compensation costs, certain procurement costs and other miscellaneous operating expenses not charged to our operating segments, as well as interest income and expense.
•Certain transactions and events such as (i) Purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment; (ii) Acquisition and divestiture-related costs, where we incur costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs, as well as divestiture-related costs; and (iii) Certain significant items, which comprise substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis, such as restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition or divestiture, certain asset impairment charges, certain legal and commercial settlements and the impact of divestiture-related gains and losses.
•Other unallocated includes (i) certain overhead expenses associated with our global manufacturing operations not charged to our operating segments; (ii) certain costs associated with finance that specifically support our global manufacturing operations; (iii) certain supply chain and global logistics costs; and (iv) certain procurement costs.
18 |
Table of Contents
Segment Assets
We manage our assets on a total company basis, not by operating segment. Therefore, our CODM does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment.
Selected Statement of Income Information
| Earnings | Depreciation and Amortization(a) | |||||||||||||||||||||||||
| Three Months Ended | Three Months Ended | |||||||||||||||||||||||||
| June 30, | June 30, | |||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||||
| U.S. | ||||||||||||||||||||||||||
| Revenue | $ | $ | ||||||||||||||||||||||||
| Cost of sales | ||||||||||||||||||||||||||
| Gross profit | ||||||||||||||||||||||||||
| Gross margin | % | % | ||||||||||||||||||||||||
Operating expenses(b) | ||||||||||||||||||||||||||
| Other (income)/deductions-net | ||||||||||||||||||||||||||
| U.S. Earnings | $ | $ | ||||||||||||||||||||||||
| International | ||||||||||||||||||||||||||
Revenue(c) | ||||||||||||||||||||||||||
| Cost of sales | ||||||||||||||||||||||||||
| Gross profit | ||||||||||||||||||||||||||
| Gross margin | % | % | ||||||||||||||||||||||||
Operating expenses(b) | ||||||||||||||||||||||||||
| Other (income)/deductions-net | ||||||||||||||||||||||||||
| International Earnings | ||||||||||||||||||||||||||
| Total operating segments | ||||||||||||||||||||||||||
Other business activities | ( | ( | ||||||||||||||||||||||||
| Reconciling Items: | ||||||||||||||||||||||||||
Corporate | ( | ( | ||||||||||||||||||||||||
Purchase accounting adjustments | ( | ( | ||||||||||||||||||||||||
Acquisition and divestiture-related costs | ( | ( | ||||||||||||||||||||||||
Certain significant items | ( | ( | ||||||||||||||||||||||||
Other unallocated | ( | ( | ||||||||||||||||||||||||
Total Earnings(d) | $ | $ | $ | $ | ||||||||||||||||||||||
(a) Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized.
(b) Operating expenses primarily consisted of field selling, advertising and promotions, other marketing expenses, and freight and logistics costs.
(c) Revenue denominated in euros was $241 million and $237 million for the three months ended June 30, 2025 and 2024, respectively.
(d) Defined as income before provision for taxes on income.
19 |
Table of Contents
| Earnings | Depreciation and Amortization(a) | |||||||||||||||||||||||||
| Six Months Ended | Six Months Ended | |||||||||||||||||||||||||
| June 30, | June 30, | |||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||||
| U.S. | ||||||||||||||||||||||||||
| Revenue | $ | $ | ||||||||||||||||||||||||
| Cost of sales | ||||||||||||||||||||||||||
| Gross profit | ||||||||||||||||||||||||||
| Gross margin | % | % | ||||||||||||||||||||||||
Operating expenses(b) | ||||||||||||||||||||||||||
| Other (income)/deductions-net | ||||||||||||||||||||||||||
| U.S. Earnings | $ | $ | ||||||||||||||||||||||||
| International | ||||||||||||||||||||||||||
Revenue(c) | ||||||||||||||||||||||||||
| Cost of sales | ||||||||||||||||||||||||||
| Gross profit | ||||||||||||||||||||||||||
| Gross margin | % | % | ||||||||||||||||||||||||
Operating expenses(b) | ||||||||||||||||||||||||||
| Other (income)/deductions-net | ||||||||||||||||||||||||||
| International Earnings | ||||||||||||||||||||||||||
| Total operating segments | ||||||||||||||||||||||||||
Other business activities | ( | ( | ||||||||||||||||||||||||
| Reconciling Items: | ||||||||||||||||||||||||||
Corporate | ( | ( | ||||||||||||||||||||||||
Purchase accounting adjustments | ( | ( | ||||||||||||||||||||||||
Acquisition and divestiture-related costs | ( | ( | ||||||||||||||||||||||||
Certain significant items | ( | ( | ||||||||||||||||||||||||
Other unallocated | ( | ( | ||||||||||||||||||||||||
Total Earnings(d) | $ | $ | $ | $ | ||||||||||||||||||||||
(a) Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized.
(b) Operating expenses primarily consisted of field selling, advertising and promotions, other marketing expenses, and freight and logistics costs.
(c) Revenue denominated in euros was $468 million and $460 million for the six months ended June 30, 2025 and 2024, respectively.
17. Subsequent Event
20 |
Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Overview of our business
Zoetis is a global leader in the animal health industry, focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. For over 70 years, we have been innovating ways to predict, prevent, detect, and treat animal illness, and continue to stand by those raising and caring for animals worldwide - from veterinarians and pet owners to livestock producers.
We manage our operations through two geographic operating segments: the United States (U.S.) and International. Within each of these operating segments, we offer a diversified product portfolio for both companion animal and livestock customers in order to capitalize on local and regional trends and customer needs. See Notes to Condensed Consolidated Financial Statements — Note 16. Segment Information.
We directly market our products to veterinarians and livestock producers located in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America, and are a market leader in nearly all of the major regions in which we operate. Through our efforts to establish an early and direct presence in many emerging markets, such as Brazil, Chile, China and Mexico, we believe we are one of the largest animal health medicines and vaccines businesses as measured by revenue across emerging markets as a whole. In markets where we do not have a direct commercial presence, we generally contract with distributors that provide logistics and sales and marketing support for our products.
Our companion animal and livestock products are primarily available by prescription through a veterinarian. On a more limited basis, in certain markets, we sell certain products through retail and e-commerce outlets. We also market our products by advertising to veterinarians, pet owners and livestock producers.
We believe our investments in one of the industry’s largest sales organizations, including our extensive network of technical and veterinary operations specialists, our high-quality manufacturing and reliability of supply, and our long track record of developing products that meet customer needs, has led to enduring and valued relationships with our customers. Our research and development (R&D) efforts enable us to deliver innovative products to address unmet needs and evolve our product lines so that they remain relevant for our customers.
We have approximately 300 product lines that we sell in over 100 countries for the prediction, prevention, detection and treatment of diseases and conditions that affect various companion animal and livestock species. The diversity of our product portfolio and our global operations provides stability to our overall business.
A summary of our 2025 performance compared with the comparable 2024 periods follows:
| % Change | ||||||||||||||||||||||||||||||||
| Three Months Ended | Related to | |||||||||||||||||||||||||||||||
| June 30, | Foreign | |||||||||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | Total | Exchange | Operational(a) | |||||||||||||||||||||||||||
| Revenue | $ | 2,460 | $ | 2,361 | 4 | (1) | 5 | |||||||||||||||||||||||||
| Net income attributable to Zoetis | 718 | 624 | 15 | 5 | 10 | |||||||||||||||||||||||||||
Adjusted net income(a) | 783 | 711 | 10 | 3 | 7 | |||||||||||||||||||||||||||
| % Change | ||||||||||||||||||||||||||||||||
| Six Months Ended | Related to | |||||||||||||||||||||||||||||||
| June 30, | Foreign | |||||||||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | Total | Exchange | Operational(a) | |||||||||||||||||||||||||||
| Revenue | $ | 4,680 | $ | 4,551 | 3 | (2) | 5 | |||||||||||||||||||||||||
| Net income attributable to Zoetis | 1,349 | 1,223 | 10 | 4 | 6 | |||||||||||||||||||||||||||
Adjusted net income(a) | 1,445 | 1,345 | 7 | 3 | 4 | |||||||||||||||||||||||||||
(a) Operational results and adjusted net income are non-GAAP financial measures. See the Non-GAAP financial measures section of this Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) for more information.
Our operating environment
For a description of our operating environment, including factors which could materially affect our business, financial condition, or future results, see "Our Operating Environment" in the MD&A of our 2024 Annual Report on Form 10-K. Set forth below are updates to certain of the factors disclosed in our 2024 Annual Report on Form 10-K.
Quarterly Variability of Financial Results
Our quarterly financial results are subject to variability related to a number of factors including, but not limited to: tariffs and other trade protection measures, the decline in global macroeconomic conditions, competitive dynamics, geopolitical tensions with and economic uncertainty in certain markets, inflation, global supply chain disruption, variability in distributor inventory stocking levels as a result of expected demand and promotional activities, weather patterns, herd management decisions, regulatory actions, disease outbreaks, product and geographic mix, timing of price increases and timing of investment decisions.
Tariffs and Trade Protection Measures
Our business is subject to risks related to, among other factors, tariffs and other trade protection measures put in the place by the United States or other countries, as well as U.S. international trade relations, including those with China, Canada and the European Union. Starting in early 2025, the
21 |
Table of Contents
United States government announced additional tariffs on certain goods imported into the U.S. from numerous countries and multiple nations countered with reciprocal tariffs and other actions in response. While the final tariffs and other measures to be imposed, and their applicability to our business, remain uncertain, such actions may negatively impact demand and result in an increase in some product costs. We will continue to actively monitor the situation and evaluate actions that can be taken to moderate and/or minimize its effects. For further information regarding the impact of potential additional tariffs and trade protection measures on the Company, see Part II., Item 1A, Risk Factors in this Quarterly Report on Form 10-Q.
Disease Outbreaks
Sales of our livestock products have in the past, and may in the future be, adversely affected by the outbreak of disease carried by animals. Outbreaks of disease may reduce regional or global sales of particular animal-derived food products or result in reduced exports of such products, either due to heightened export restrictions or import prohibitions, which may reduce demand for our products. Also, the outbreak of any highly contagious disease near our main production sites could require us to immediately halt production of our products at such sites or force us to incur substantial expenses in procuring raw materials or products elsewhere. Alternatively, sales of products that treat specific disease outbreaks may increase.
Foreign Exchange Rates
Significant portions of our revenue and costs are exposed to changes in foreign exchange rates. Our products are sold in more than 100 countries and, as a result, our revenue is influenced by changes in foreign exchange rates. For the six months ended June 30, 2025, approximately 41% of our revenue was denominated in foreign currencies. We seek to manage our foreign exchange risk, in part, through operational means, including managing same-currency revenue in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. As we operate in multiple foreign currencies, including the Australian dollar, Brazilian real, British pound, Canadian dollar, Chinese renminbi, euro and other currencies, changes in those currencies relative to the U.S. dollar will impact our revenue, cost of goods and expenses, and consequently, net income. Exchange rate fluctuations may also have an impact beyond our reported financial results and directly impact operations. These fluctuations may affect the ability to buy and sell our goods and services between markets impacted by significant exchange rate variances. For the six months ended June 30, 2025, approximately 59% of our total revenue was in U.S. dollars. Our year-over-year total revenue growth was unfavorably impacted by approximately 2% from changes in foreign currency values relative to the U.S. dollar. For operations in highly inflationary economies, we translate monetary items at rates in effect at the balance sheet date, with translation adjustments recorded in Other (income)/deductions––net, and we translate non-monetary items at historical rates.
Non-GAAP financial measures
We report information in accordance with U.S. generally accepted accounting principles (GAAP). Management also measures performance using non-GAAP financial measures that may exclude certain amounts from the most directly comparable GAAP measure. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP financial measures have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors and may not be comparable to the calculation of similar measures of other companies. We present certain identified non-GAAP measures solely to provide investors with useful information to more fully understand how management assesses performance.
Operational Results
We believe that it is important to not only understand overall revenue and earnings results, but also “operational” results. Operational results is a non-GAAP financial measure defined as revenue or earnings results excluding the impact of foreign exchange. This measure provide information on the change in revenue and earnings as if foreign currency exchange rates had not changed between the current and prior periods to facilitate a period-to-period comparison. We believe this non-GAAP measure provides a useful comparison to previous periods for the company and investors, but should not be viewed as a substitute for U.S. GAAP reported results.
Adjusted Net Income and Adjusted Earnings Per Share
Adjusted net income and the corresponding adjusted earnings per share (EPS) are non-GAAP financial measures of performance used by management. We believe these financial measures are useful supplemental information to investors when considered together with our U.S. GAAP financial measures. We report adjusted net income to portray the results of our major operations, and the discovery, development, manufacture and commercialization of our products, prior to considering certain income statement elements. We define adjusted net income and adjusted EPS as net income attributable to Zoetis and EPS before the impact of purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items.
We recognize that, as an internal measure of performance, the adjusted net income and adjusted EPS measures have limitations, and we do not restrict our performance management process solely to these metrics. A limitation of the adjusted net income and adjusted EPS measures is that they provide a view of our operations without including all events during a period, such as the effects of an acquisition, divestiture or amortization of purchased intangibles, and do not provide a comparable view of our performance to other companies. The adjusted net income and adjusted EPS measures are not, and should not be viewed as, a substitute for U.S. GAAP reported net income attributable to Zoetis and reported EPS. See the Adjusted Net Income section below for more information.
22 |
Analysis of the condensed consolidated statements of income
The following discussion and analysis of our statements of income should be read along with our condensed consolidated financial statements and the notes thereto included elsewhere in Part I— Item 1 of this Quarterly Report on Form 10-Q.
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||||||||||||
| June 30, | % | June 30, | % | |||||||||||||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | Change | 2025 | 2024 | Change | ||||||||||||||||||||||||||||||||
| Revenue | $ | 2,460 | $ | 2,361 | 4 | $ | 4,680 | $ | 4,551 | 3 | ||||||||||||||||||||||||||||
| Costs and expenses: | ||||||||||||||||||||||||||||||||||||||
| Cost of sales | 649 | 668 | (3) | 1,271 | 1,311 | (3) | ||||||||||||||||||||||||||||||||
| % of revenue | 26.4 | % | 28.3 | % | 27.2 | % | 28.8 | % | ||||||||||||||||||||||||||||||
| Selling, general and administrative expenses | 617 | 581 | 6 | 1,180 | 1,128 | 5 | ||||||||||||||||||||||||||||||||
| % of revenue | 25 | % | 25 | % | 25 | % | 25 | % | ||||||||||||||||||||||||||||||
| Research and development expenses | 172 | 171 | 1 | 329 | 333 | (1) | ||||||||||||||||||||||||||||||||
| % of revenue | 7 | % | 7 | % | 7 | % | 7 | % | ||||||||||||||||||||||||||||||
| Amortization of intangible assets | 33 | 35 | (6) | 65 | 72 | (10) | ||||||||||||||||||||||||||||||||
| Restructuring charges and certain acquisition and divestiture-related costs | 30 | 42 | (29) | 30 | 46 | (35) | ||||||||||||||||||||||||||||||||
| Interest expense, net of capitalized interest | 53 | 59 | (10) | 107 | 117 | (9) | ||||||||||||||||||||||||||||||||
| Other (income)/deductions—net | 4 | 25 | (84) | (14) | 17 | * | ||||||||||||||||||||||||||||||||
| Income before provision for taxes on income | 902 | 780 | 16 | 1,712 | 1,527 | 12 | ||||||||||||||||||||||||||||||||
| % of revenue | 37 | % | 33 | % | 37 | % | 34 | % | ||||||||||||||||||||||||||||||
| Provision for taxes on income | 184 | 156 | 18 | 363 | 304 | 19 | ||||||||||||||||||||||||||||||||
| Effective tax rate | 20.4 | % | 20.0 | % | 21.2 | % | 19.9 | % | ||||||||||||||||||||||||||||||
| Net income before allocation to noncontrolling interests | 718 | 624 | 15 | 1,349 | 1,223 | 10 | ||||||||||||||||||||||||||||||||
| Less: Net income/(loss) attributable to noncontrolling interests | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||
| Net income attributable to Zoetis | $ | 718 | $ | 624 | 15 | $ | 1,349 | $ | 1,223 | 10 | ||||||||||||||||||||||||||||
| % of revenue | 29 | % | 26 | % | 29 | % | 27 | % | ||||||||||||||||||||||||||||||
*Calculation not meaningful
Revenue
Three months ended June 30, 2025 vs. three months ended June 30, 2024
Total revenue increased by $99 million, or 4%, in the three months ended June 30, 2025, compared with the three months ended June 30, 2024, an increase of $113, or 5%, on an operational basis. Operational revenue growth was primarily due to the following:
•price growth of approximately 4%;
•volume growth from key franchises of approximately 3%; and
•volume growth from other in-line products of approximately 2%,
partially offset by:
•volume decrease related to the impact of the divestiture of our medicated feed additive product portfolio, certain water soluble products and related assets (MFA divestiture) of approximately 4%.
Foreign exchange decreased reported revenue growth by approximately 1%.
Six months ended June 30, 2025 vs. six months ended June 30, 2024
Total revenue increased by $129 million, or 3%, in the six months ended June 30, 2025, compared with the six months ended June 30, 2024, an increase of $216 million, or 5%, on an operational basis. Operational revenue growth was primarily due to the following:
•price growth of approximately 4%;
•volume growth from key franchises of approximately 3%; and
•volume growth from other in-line products of approximately 2%,
partially offset by:
•volume decrease related to the impact of the MFA divestiture of approximately 4%.
Foreign exchange decreased reported revenue growth by approximately 2%.
23 |
Table of Contents
Costs and Expenses
Cost of sales | ||||||||||||||||||||||||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||||||||||||
| June 30, | % | June 30, | % | |||||||||||||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | Change | 2025 | 2024 | Change | ||||||||||||||||||||||||||||||||
| Cost of sales | $ | 649 | $ | 668 | (3) | $ | 1,271 | $ | 1,311 | (3) | ||||||||||||||||||||||||||||
| % of revenue | 26.4 | % | 28.3 | % | 27.2 | % | 28.8 | % | ||||||||||||||||||||||||||||||
Three months ended June 30, 2025 vs. three months ended June 30, 2024
Cost of sales as a percentage of revenue was 26.4% in the three months ended June 30, 2025, compared with 28.3% in the three months ended June 30, 2024. The decrease was primarily a result of:
•favorable impact of the MFA divestiture;
•favorable foreign exchange; and
•price increases,
partially offset by:
•unfavorable manufacturing and other costs.
Six months ended June 30, 2025 vs. six months ended June 30, 2024
Cost of sales as a percentage of revenue was 27.2% in the six months ended June 30, 2025, compared with 28.8% in the six months ended June 30, 2024. The decrease was primarily a result of:
•favorable foreign exchange;
•favorable impact of the MFA divestiture; and
•price increases,
partially offset by:
•unfavorable manufacturing and other costs.
Selling, general and administrative expenses | ||||||||||||||||||||||||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||||||||||||
| June 30, | % | June 30, | % | |||||||||||||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | Change | 2025 | 2024 | Change | ||||||||||||||||||||||||||||||||
| Selling, general and administrative expenses | $ | 617 | $ | 581 | 6 | $ | 1,180 | $ | 1,128 | 5 | ||||||||||||||||||||||||||||
| % of revenue | 25 | % | 25 | % | 25 | % | 25 | % | ||||||||||||||||||||||||||||||
Three months ended June 30, 2025 vs. three months ended June 30, 2024
SG&A expenses increased by $36 million, or 6%, in the three months ended June 30, 2025, compared with the three months ended June 30, 2024, primarily as a result of:
•higher advertising and promotion expenses;
•an increase in certain significant items;
•an increase in certain compensation-related costs; and
•higher other general and administrative costs,
partially offset by:
•favorable foreign exchange;
•lower bad debt expense; and
•lower logistics and freight costs.
Six months ended June 30, 2025 vs. six months ended June 30, 2024
SG&A expenses increased by $52 million, or 5%, in the six months ended June 30, 2025, compared with the six months ended June 30, 2024, primarily as a result of:
•higher advertising and promotion expenses;
•an increase in certain significant items;
•an increase in certain compensation-related costs;
•higher travel and entertainment costs; and
•higher other general and administrative costs,
partially offset by:
•favorable foreign exchange;
•lower logistics and freight costs; and
•lower bad debt expense.
24 |
Table of Contents
Research and development expenses | ||||||||||||||||||||||||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||||||||||||
| June 30, | % | June 30, | % | |||||||||||||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | Change | 2025 | 2024 | Change | ||||||||||||||||||||||||||||||||
| Research and development expenses | $ | 172 | $ | 171 | 1 | $ | 329 | $ | 333 | (1) | ||||||||||||||||||||||||||||
| % of revenue | 7 | % | 7 | % | 7 | % | 7 | % | ||||||||||||||||||||||||||||||
Three months ended June 30, 2025 vs. three months ended June 30, 2024
R&D expenses increased by $1 million, or 1%, in the three months ended June 30, 2025, compared with the three months ended June 30, 2024, primarily as a result of:
•an increase in certain compensation-related costs to support innovation and portfolio progression; and
•higher depreciation expense,
partially offset by:
•lower expenses due to timing of spend related to projects and other strategic investments.
Six months ended June 30, 2025 vs. six months ended June 30, 2024
R&D expenses decreased by $4 million, or 1%, in the six months ended June 30, 2025, compared with the six months ended June 30, 2024, primarily as a result of:
•lower expenses due to timing of spend related to projects and other strategic investments,
partially offset by:
•an increase in certain compensation-related costs to support innovation and portfolio progression; and
•higher depreciation expense.
Amortization of intangible assets | ||||||||||||||||||||||||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||||||||||||
| June 30, | % | June 30, | % | |||||||||||||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | Change | 2025 | 2024 | Change | ||||||||||||||||||||||||||||||||
| Amortization of intangible assets | $ | 33 | $ | 35 | (6) | $ | 65 | $ | 72 | (10) | ||||||||||||||||||||||||||||
Amortization of intangible assets decreased in the three and six months ended June 30, 2025 and 2024 versus the comparable prior year periods primarily due to assets that became fully amortized in the prior year.
Restructuring charges and certain acquisition and divestiture-related costs | ||||||||||||||||||||||||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||||||||||||
| June 30, | % | June 30, | % | |||||||||||||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | Change | 2025 | 2024 | Change | ||||||||||||||||||||||||||||||||
| Restructuring charges and certain acquisition and divestiture-related costs | $ | 30 | $ | 42 | (29) | $ | 30 | $ | 46 | (35) | ||||||||||||||||||||||||||||
Restructuring charges and certain acquisition and divestiture-related costs in the three and six months ended June 30, 2025 primarily consisted of asset impairment charges and employee termination costs related to a transition from internal to external innovation and manufacturing of certain products and the closure of a related site.
Restructuring charges and certain acquisition and divestiture-related costs in the three and six months ended June 30, 2024 primarily consisted of employee termination costs related to organizational structure refinements, as well as costs related to the MFA divestiture. Restructuring charges and certain acquisition and divestiture-related costs for the six months ended June 30, 2024 were partially offset by a reversal of certain employee termination costs as a result of a change in strategy from our 2015 operational efficiency initiative.
| Interest expense, net of capitalized interest | ||||||||||||||||||||||||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||||||||||||
| June 30, | % | June 30, | % | |||||||||||||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | Change | 2025 | 2024 | Change | ||||||||||||||||||||||||||||||||
| Interest expense, net of capitalized interest | $ | 53 | $ | 59 | (10) | $ | 107 | $ | 117 | (9) | ||||||||||||||||||||||||||||
Interest expense, net of capitalized interest, decreased in the three and six months ended June 30, 2025 versus the comparable prior year periods primarily as a result of higher capitalized interest in the current periods associated with capital projects to support our future growth.
25 |
Table of Contents
Other (income)/deductions—net | ||||||||||||||||||||||||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||||||||||||
| June 30, | % | June 30, | % | |||||||||||||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | Change | 2025 | 2024 | Change | ||||||||||||||||||||||||||||||||
| Other (income)/deductions—net | $ | 4 | $ | 25 | (84) | $ | (14) | $ | 17 | * | ||||||||||||||||||||||||||||
The change in Other (income)/deductions—net in the three and six months ended June 30, 2025 versus the comparable prior year periods was primarily as a result of the net loss on the sale of our medicated feed additive product portfolio, certain water soluble products and related assets sold in 2024 and lower foreign currency losses in the current periods, partially offset by lower interest income in the current periods.
Provision for taxes on income | ||||||||||||||||||||||||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||||||||||||
| June 30, | % | June 30, | % | |||||||||||||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | Change | 2025 | 2024 | Change | ||||||||||||||||||||||||||||||||
Provision for taxes on income | $ | 184 | $ | 156 | 18 | $ | 363 | $ | 304 | 19 | ||||||||||||||||||||||||||||
Effective tax rate | 20.4 | % | 20.0 | % | 21.2 | % | 19.9 | % | ||||||||||||||||||||||||||||||
Our effective tax rate was 20.4% and 20.0% for the three months ended June 30, 2025 and 2024, respectively, and 21.2% and 19.9% for the six months ended June 30, 2025 and 2024, respectively. The higher effective tax rate for the three and six months ended June 30, 2025, compared with the three and six months ended June 30, 2024, was primarily attributable to a lower benefit in the U.S. related to foreign-derived intangible income, higher net discrete tax expenses, partially offset by a more favorable jurisdictional mix of earnings (which includes the impact of the location of pre-tax earnings, tax impact of permanent differences and repatriation decisions).
26 |
Table of Contents
Operating Segment Results
On a global basis, the mix of revenue between companion animal and livestock products was as follows:
| % Change | |||||||||||||||||||||||||||||||||||
| Three Months Ended | Related to | ||||||||||||||||||||||||||||||||||
| June 30, | Foreign | ||||||||||||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | Total | Exchange | Operational | ||||||||||||||||||||||||||||||
| U.S. | |||||||||||||||||||||||||||||||||||
| Companion animal | $ | 1,176 | $ | 1,080 | 9 | — | 9 | ||||||||||||||||||||||||||||
| Livestock | 180 | 228 | (21) | — | (21) | ||||||||||||||||||||||||||||||
| 1,356 | 1,308 | 4 | — | 4 | |||||||||||||||||||||||||||||||
| International | |||||||||||||||||||||||||||||||||||
| Companion animal | 612 | 569 | 8 | — | 8 | ||||||||||||||||||||||||||||||
| Livestock | 458 | 466 | (2) | (3) | 1 | ||||||||||||||||||||||||||||||
| 1,070 | 1,035 | 3 | (2) | 5 | |||||||||||||||||||||||||||||||
| Total | |||||||||||||||||||||||||||||||||||
| Companion animal | 1,788 | 1,649 | 8 | — | 8 | ||||||||||||||||||||||||||||||
| Livestock | 638 | 694 | (8) | (2) | (6) | ||||||||||||||||||||||||||||||
| Contract manufacturing & human health | 34 | 18 | 89 | (2) | 91 | ||||||||||||||||||||||||||||||
| $ | 2,460 | $ | 2,361 | 4 | (1) | 5 | |||||||||||||||||||||||||||||
| % Change | |||||||||||||||||||||||||||||||||||
| Six Months Ended | Related to | ||||||||||||||||||||||||||||||||||
| June 30, | Foreign | ||||||||||||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | Total | Exchange | Operational | ||||||||||||||||||||||||||||||
| U.S. | |||||||||||||||||||||||||||||||||||
| Companion animal | $ | 2,149 | $ | 1,978 | 9 | — | 9 | ||||||||||||||||||||||||||||
| Livestock | 390 | 493 | (21) | — | (21) | ||||||||||||||||||||||||||||||
| 2,539 | 2,471 | 3 | — | 3 | |||||||||||||||||||||||||||||||
| International | |||||||||||||||||||||||||||||||||||
| Companion animal | 1,185 | 1,121 | 6 | (3) | 9 | ||||||||||||||||||||||||||||||
| Livestock | 893 | 921 | (3) | (5) | 2 | ||||||||||||||||||||||||||||||
| 2,078 | 2,042 | 2 | (4) | 6 | |||||||||||||||||||||||||||||||
| Total | |||||||||||||||||||||||||||||||||||
| Companion animal | 3,334 | 3,099 | 8 | (1) | 9 | ||||||||||||||||||||||||||||||
| Livestock | 1,283 | 1,414 | (9) | (3) | (6) | ||||||||||||||||||||||||||||||
| Contract manufacturing & human health | 63 | 38 | 66 | (4) | 70 | ||||||||||||||||||||||||||||||
| $ | 4,680 | $ | 4,551 | 3 | (2) | 5 | |||||||||||||||||||||||||||||
27 |
Table of Contents
Earnings by segment and the operational and foreign exchange changes versus the comparable prior year period were as follows:
| % Change | |||||||||||||||||||||||||||||||||||
| Three Months Ended | Related to | ||||||||||||||||||||||||||||||||||
| June 30, | Foreign | ||||||||||||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | Total | Exchange | Operational | ||||||||||||||||||||||||||||||
| U.S. | |||||||||||||||||||||||||||||||||||
| Revenue | $ | 1,356 | $ | 1,308 | 4 | — | 4 | ||||||||||||||||||||||||||||
| Cost of Sales | 208 | 232 | (10) | — | (10) | ||||||||||||||||||||||||||||||
| Gross Profit | 1,148 | 1,076 | 7 | — | 7 | ||||||||||||||||||||||||||||||
| Gross Margin | 84.7 | % | 82.3 | % | |||||||||||||||||||||||||||||||
| Operating Expenses | 218 | 204 | 7 | — | 7 | ||||||||||||||||||||||||||||||
| Other (income)/deductions-net | — | — | * | * | * | ||||||||||||||||||||||||||||||
| U.S. Earnings | 930 | 872 | 7 | — | 7 | ||||||||||||||||||||||||||||||
| International | |||||||||||||||||||||||||||||||||||
| Revenue | 1,070 | 1,035 | 3 | (2) | 5 | ||||||||||||||||||||||||||||||
| Cost of Sales | 314 | 342 | (8) | (9) | 1 | ||||||||||||||||||||||||||||||
| Gross Profit | 756 | 693 | 9 | 2 | 7 | ||||||||||||||||||||||||||||||
| Gross Margin | 70.7 | % | 67.0 | % | |||||||||||||||||||||||||||||||
| Operating Expenses | 173 | 175 | (1) | (3) | 2 | ||||||||||||||||||||||||||||||
| Other (income)/deductions-net | — | — | * | * | * | ||||||||||||||||||||||||||||||
| International Earnings | 583 | 518 | 13 | 5 | 8 | ||||||||||||||||||||||||||||||
| Total operating segments | 1,513 | 1,390 | 9 | 2 | 7 | ||||||||||||||||||||||||||||||
| Other business activities | (134) | (142) | (6) | ||||||||||||||||||||||||||||||||
| Reconciling Items: | |||||||||||||||||||||||||||||||||||
| Corporate | (321) | (299) | 7 | ||||||||||||||||||||||||||||||||
| Purchase accounting adjustments | (33) | (35) | (6) | ||||||||||||||||||||||||||||||||
| Acquisition and divestiture-related costs | (1) | (5) | (80) | ||||||||||||||||||||||||||||||||
| Certain significant items | (47) | (70) | (33) | ||||||||||||||||||||||||||||||||
| Other unallocated | (75) | (59) | 27 | ||||||||||||||||||||||||||||||||
| Total Earnings | $ | 902 | $ | 780 | 16 | ||||||||||||||||||||||||||||||
* Calculation not meaningful
28 |
Table of Contents
| % Change | |||||||||||||||||||||||||||||||||||
| Six Months Ended | Related to | ||||||||||||||||||||||||||||||||||
| June 30, | Foreign | ||||||||||||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | Total | Exchange | Operational | ||||||||||||||||||||||||||||||
| U.S. | |||||||||||||||||||||||||||||||||||
| Revenue | $ | 2,539 | $ | 2,471 | 3 | — | 3 | ||||||||||||||||||||||||||||
| Cost of Sales | 407 | 449 | (9) | — | (9) | ||||||||||||||||||||||||||||||
| Gross Profit | 2,132 | 2,022 | 5 | — | 5 | ||||||||||||||||||||||||||||||
| Gross Margin | 84.0 | % | 81.8 | % | |||||||||||||||||||||||||||||||
| Operating Expenses | 423 | 394 | 7 | — | 7 | ||||||||||||||||||||||||||||||
| Other (income)/deductions-net | — | — | * | * | * | ||||||||||||||||||||||||||||||
| U.S. Earnings | 1,709 | 1,628 | 5 | — | 5 | ||||||||||||||||||||||||||||||
| International | |||||||||||||||||||||||||||||||||||
| Revenue | 2,078 | 2,042 | 2 | (4) | 6 | ||||||||||||||||||||||||||||||
| Cost of Sales | 616 | 655 | (6) | (11) | 5 | ||||||||||||||||||||||||||||||
| Gross Profit | 1,462 | 1,387 | 5 | (1) | 6 | ||||||||||||||||||||||||||||||
| Gross Margin | 70.4 | % | 67.9 | % | |||||||||||||||||||||||||||||||
| Operating Expenses | 327 | 334 | (2) | (5) | 3 | ||||||||||||||||||||||||||||||
| Other (income)/deductions-net | 1 | — | * | * | * | ||||||||||||||||||||||||||||||
| International Earnings | 1,134 | 1,053 | 8 | 1 | 7 | ||||||||||||||||||||||||||||||
| Total operating segments | 2,843 | 2,681 | 6 | — | 6 | ||||||||||||||||||||||||||||||
| Other business activities | (263) | (274) | (4) | ||||||||||||||||||||||||||||||||
| Reconciling Items: | |||||||||||||||||||||||||||||||||||
| Corporate | (592) | (587) | 1 | ||||||||||||||||||||||||||||||||
| Purchase accounting adjustments | (65) | (72) | (10) | ||||||||||||||||||||||||||||||||
| Acquisition and divestiture-related costs | (1) | (5) | (80) | ||||||||||||||||||||||||||||||||
| Certain significant items | (53) | (76) | (30) | ||||||||||||||||||||||||||||||||
| Other unallocated | (157) | (140) | 12 | ||||||||||||||||||||||||||||||||
| Total Earnings | $ | 1,712 | $ | 1,527 | 12 | ||||||||||||||||||||||||||||||
* Calculation not meaningful
Three months ended June 30, 2025 vs. three months ended June 30, 2024
U.S. operating segment
U.S. segment revenue increased by $48 million, or 4%, in the three months ended June 30, 2025, compared with the three months ended June 30, 2024, reflecting an increase of $96 million in companion animal products, partially offset by a $48 million reduction in livestock products.
•Companion animal revenue increased primarily due to increased sales of Simparica Trio®, key dermatology products and small animal vaccines, partially offset by lower sales of our mAb products for OA pain, Librela® and Solensia®.
•Livestock revenue decreased primarily due to the impact of the MFA divestiture across cattle, poultry and swine products.
U.S. segment earnings increased by $58 million, or 7%, in the three months ended June 30, 2025, compared with the three months ended June 30, 2024, primarily due to higher revenue and lower cost of sales, partially offset by higher operating expenses, as well as the impact of the MFA divestiture.
International operating segment
International segment revenue increased by $35 million in the three months ended June 30, 2025 compared with the three months ended June 30, 2024. Operational revenue increased by $49 million, or 5%, driven by growth of $44 million in companion animal products and $5 million in livestock products.
•Companion animal operational revenue growth was driven primarily by increased sales of our key dermatology products and our Simparica® franchise products.
•Livestock operational revenue growth was due to increased sales in our fish and swine products, partially offset by lower sales of poultry products. Excluding the impact of the MFA divestiture, livestock revenue increased across all species. Sales of swine products increased due to timing of the expected impact of macroenvironment conditions, primarily in China. Sales of our fish products grew due to increased vaccine sales in Norway and Chile. Sales of poultry products grew due to higher demand for vaccines in key poultry markets, as well as price, and sales of cattle products grew largely due to price.
•Additionally, International segment revenue was unfavorably impacted by foreign exchange which decreased revenue by $14 million, or 2%, primarily driven by the Brazilian real, Mexican peso, Argentinian peso and Turkish lira.
29 |
Table of Contents
International segment earnings increased by $65 million, or 13%, in the three months ended June 30, 2025, compared with the three months ended June 30, 2024. Operational earnings growth was $41 million, or 8%, primarily due to higher revenue, partially offset by higher cost of sales and operating expenses, as well as the impact of the MFA divestiture.
Six months ended June 30, 2025 vs. six months ended June 30, 2024
U.S. operating segment
U.S. segment revenue increased by $68 million, or 3%, in the six months ended June 30, 2025, compared with the six months ended June 30, 2024, reflecting an increase of $171 million in companion animal products, partially offset by a $103 million reduction in livestock products.
•Companion animal revenue growth was primarily due to increased sales of Simparica Trio, key dermatology products and small animal diagnostics, partially offset by lower sales of our small animal vaccines.
•Livestock revenue declined primarily due to the impact of the MFA divestiture across cattle, poultry and swine products.
U.S. segment earnings increased by $81 million, or 5%, in the six months ended June 30, 2025, compared with the six months ended June 30, 2024, primarily due to higher revenue and lower cost of sales, partially offset by higher operating expenses, as well as the impact of the MFA divestiture.
International operating segment
International segment revenue increased by $36 million in the six months ended June 30, 2025 compared with the six months ended June 30, 2024. Operational revenue increased by $122 million, or 6%, driven by growth of $100 million in companion animal products and $22 million in livestock products.
•Companion animal operational revenue growth was driven primarily by increased sales of our Simparica franchise products, key dermatology products and our mAb products for OA pain, Librela and Solensia.
•Livestock operational revenue growth was due to increased sales in our cattle and fish products, partially offset by lower sales of poultry products. Excluding the impact of the MFA divestiture, livestock revenue increased across all species. Sales of cattle products grew largely due to price and sales of poultry products grew due to higher demand for vaccines in key poultry markets and price. Sales of our fish products grew due to increased vaccine sales in Norway and Chile. Sales of swine products increased due to timing of the expected impact of macroenvironment conditions, primarily in China.
•Additionally, International segment revenue was unfavorably impacted by foreign exchange which decreased revenue by $86 million, or 4%, primarily driven by the Brazilian real, Mexican peso, Argentinian peso, Turkish lira, Australian dollar and Canadian dollar.
International segment earnings increased by $81 million, or 8%, in the six months ended June 30, 2025, compared with the six months ended June 30, 2024. Operational earnings growth was $76 million, or 7%, primarily due to higher revenue, partially offset by higher cost of sales and operating expenses, as well as the impact of the MFA divestiture.
Other business activities
Other business activities includes our Client Supply Services contract manufacturing results, our human health business and expenses associated with our dedicated veterinary medicine research and development organization, research alliances, U.S. regulatory affairs and other operations focused on the development of our products. Other R&D-related costs associated with non-U.S. market and regulatory activities are generally included in the International segment.
Three months ended June 30, 2025 vs. three months ended June 30, 2024
Other business activities net loss decreased by $8 million in the three months ended June 30, 2025, compared with the three months ended June 30, 2024, reflecting a decrease in R&D costs primarily due to timing of spend related to projects and other strategic investments, partially offset by an increase in certain compensation-related costs and depreciation expense.
Six months ended June 30, 2025 vs. six months ended June 30, 2024
Other business activities net loss decreased by $11 million in the six months ended June 30, 2025, compared with the six months ended June 30, 2024, reflecting a decrease in R&D costs primarily due to timing of spend related to projects and other strategic investments, partially offset by an increase in certain compensation-related costs and depreciation expense.
Reconciling items
Reconciling items include certain costs that are not allocated to our operating segments results, such as costs associated with the following:
•Corporate, which includes certain costs associated with information technology, facilities, legal, finance, human resources, business development, certain diagnostic costs and communications, among others. These costs also include certain compensation costs, certain procurement costs, and other miscellaneous operating expenses that are not charged to our operating segments, as well as interest income and expense;
•Certain transactions and events such as Purchase accounting adjustments, Acquisition and divestiture-related costs and Certain significant items, which are defined below; and
•Other unallocated, which includes (i) certain overhead expenses associated with our global manufacturing operations not charged to our operating segments; (ii) certain costs associated with finance that specifically support our global manufacturing operations; (iii) certain supply chain and global logistics costs; and (iv) certain procurement costs.
Three months ended June 30, 2025 vs. three months ended June 30, 2024
Corporate expenses increased by $22 million, or 7%, in the three months ended June 30, 2025, compared with the three months ended June 30, 2024, primarily due to increased investments in information technology and higher compensation related costs, partially offset by favorable foreign exchange.
30 |
Table of Contents
Other unallocated expenses increased by $16 million, or 27%, in the three months ended June 30, 2025, compared with the three months ended June 30, 2024, primarily due to higher manufacturing costs and other charges, partially offset by lower inventory obsolescence, freight charges and favorable foreign exchange.
Six months ended June 30, 2025 vs. six months ended June 30, 2024
Corporate expenses increased by $5 million, or 1%, in the six months ended June 30, 2025, compared with the six months ended June 30, 2024, primarily due to increased investments in information technology.
Other unallocated expenses increased by $17 million, or 12%, in the six months ended June 30, 2025, compared with the six months ended June 30, 2024, primarily due to higher manufacturing costs and other charges, partially offset by lower inventory obsolescence, freight charges and favorable foreign exchange.
See Notes to Condensed Consolidated Financial Statements—Note 16. Segment Information for further information.
Adjusted net income
General description of adjusted net income (a non-GAAP financial measure)
Adjusted net income is an alternative view of performance used by management, and we believe that investors’ understanding of our performance is enhanced by disclosing this performance measure. The adjusted net income measure is an important internal measurement for us. Additionally, we measure our overall performance on this basis in conjunction with other performance metrics. The following are examples of how the adjusted net income measure is utilized:
•senior management receives a monthly analysis of our operating results that is prepared on an adjusted net income basis;
•our annual budgets are prepared on an adjusted net income basis; and
•other goal setting and performance measurements.
Purchase accounting adjustments
Adjusted net income is calculated prior to considering certain significant purchase accounting impacts that result from business combinations and net asset acquisitions. These impacts, primarily associated with certain acquisitions, include amortization related to the increase in fair value of the acquired finite-lived intangible assets and depreciation related to the increase/decrease to fair value of the acquired fixed assets. Therefore, the adjusted net income measure includes the revenue earned upon the sale of the acquired products without considering the aforementioned significant charges.
While certain purchase accounting adjustments can occur through 20 or more years, this presentation provides an alternative view of our performance that is used by management to internally assess business performance. We believe the elimination of amortization attributable to acquired intangible assets provides management and investors an alternative view of our business results by providing a degree of parity to internally developed intangible assets for which R&D costs previously have been expensed.
A completely accurate comparison of internally developed intangible assets and acquired intangible assets cannot be achieved through adjusted net income. These components of adjusted net income are derived solely from the impact of the items listed above. We have not factored in the impact of any other differences in experience that might have occurred if we had discovered and developed those intangible assets on our own, and this approach does not intend to be representative of the results that would have occurred in those circumstances. For example, our R&D costs in total, and in the periods presented, may have been different; our speed to commercialization and resulting revenue, if any, may have been different; or our costs to manufacture may have been different. In addition, our marketing efforts may have been received differently by our customers. As such, in total, there can be no assurance that our adjusted net income amounts would have been the same as presented had we discovered and developed the acquired intangible assets.
Acquisition and divestiture-related costs
Adjusted net income is calculated prior to considering transaction, integration and disintegration costs associated with significant business combinations, net asset acquisitions and divestitures. These incremental costs are excluded as they are incurred to acquire and integrate, or dispose and disintegrate, certain businesses as a result of the acquisition or disposal decision and are unique to each transaction. We have made no adjustments for the resulting synergies from these transactions.
We believe that viewing income prior to considering these charges provides investors with a useful additional perspective because the significant costs incurred in a business combination, net asset acquisition or divestiture result primarily from the need to eliminate duplicate assets, activities or employees––a natural result of acquiring or disposing of a fully integrated set of activities. For this reason, we believe that the costs incurred to convert disparate systems, to close duplicative facilities or to eliminate duplicate positions (for example, in the context of a business combination) can be viewed differently from those costs incurred in the ordinary course of business.
The integration and disintegration costs associated with a business combination, asset acquisition or divestiture may occur over several years, with the more significant impacts generally ending within three years of the transaction. Because of the need for certain external approvals for some actions, the span of time needed to achieve certain restructuring, integration or disintegration activities can be lengthy. For example, due to the regulated nature of the animal health medicines, vaccines and diagnostic business, the closure of excess facilities can take several years, as all manufacturing changes are subject to extensive validation and testing and must be approved by the U.S. Food and Drug Administration and/or other regulatory authorities.
Certain significant items
Adjusted net income is calculated excluding certain significant items. Certain significant items represent substantive, unusual items that are evaluated on an individual basis. Such evaluation considers both the quantitative and the qualitative aspect of their unusual nature. Unusual, in this context, may represent items that are not part of our ongoing business; items that, either as a result of their nature or size, we would not expect to occur as part
31 |
Table of Contents
of our normal business on a regular basis; items that would be nonrecurring; or items that relate to products that we no longer sell. While not all-inclusive, examples of items that could be included as certain significant items would be costs related to a major non-acquisition or divestiture-related restructuring charge and associated implementation costs for a program that is specific in nature with a defined term, such as those related to our non-acquisition or divestiture-related cost-reduction and productivity initiatives; costs related to our business process transformation program; amounts related to disposals of products or facilities that do not qualify as discontinued operations as defined by U.S. GAAP; certain asset impairment charges; adjustments related to the resolution of certain tax positions; significant currency devaluation; the impact of adopting certain significant, event-driven tax legislation; or charges related to legal matters. See Notes to Condensed Consolidated Financial Statements—Note 15. Commitments and Contingencies. Our normal, ongoing defense costs or settlements of and accruals on legal matters made in the normal course of our business would not be considered certain significant items.
Reconciliation
A reconciliation of net income attributable to Zoetis, as reported under U.S. GAAP, to adjusted net income follows:
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||||||||||||
| June 30, | % | June 30, | % | |||||||||||||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | Change | 2025 | 2024 | Change | ||||||||||||||||||||||||||||||||
| GAAP reported net income attributable to Zoetis | $ | 718 | $ | 624 | 15 | $ | 1,349 | $ | 1,223 | 10 | ||||||||||||||||||||||||||||
| Purchase accounting adjustments—net of tax | 26 | 27 | (4) | 51 | 56 | (9) | ||||||||||||||||||||||||||||||||
| Acquisition and divestiture-related costs—net of tax | 1 | 4 | (75) | 1 | 4 | (75) | ||||||||||||||||||||||||||||||||
| Certain significant items—net of tax | 38 | 56 | (32) | 44 | 62 | (29) | ||||||||||||||||||||||||||||||||
Non-GAAP adjusted net income(a) | $ | 783 | $ | 711 | 10 | $ | 1,445 | $ | 1,345 | 7 | ||||||||||||||||||||||||||||
(a) The effective tax rate on adjusted pre-tax income was 20.3% and 20.1% for the three months ended June 30, 2025 and 2024, respectively, and 21.1% and 19.9% for the six months ended June 30, 2025 and 2024, respectively.
The higher effective tax rate for the three and six months ended June 30, 2025, compared with the three and six months ended June 30, 2024, was primarily attributable to a lower benefit in the U.S related to foreign-derived intangible income, higher net discrete tax expenses, partially offset by a more favorable jurisdictional mix of earnings (which includes the impact of the location of pre-tax earnings, tax impact of permanent differences and repatriation decisions).
A reconciliation of reported diluted earnings per share (EPS), as reported under U.S. GAAP, to non-GAAP adjusted diluted EPS follows:
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||||||||||||
| June 30, | % | June 30, | % | |||||||||||||||||||||||||||||||||||
| 2025 | 2024 | Change | 2025 | 2024 | Change | |||||||||||||||||||||||||||||||||
Earnings per share—diluted(a): | ||||||||||||||||||||||||||||||||||||||
| GAAP reported EPS attributable to Zoetis—diluted | $ | 1.61 | $ | 1.37 | 18 | $ | 3.02 | $ | 2.67 | 13 | ||||||||||||||||||||||||||||
| Purchase accounting adjustments—net of tax | 0.06 | 0.06 | — | 0.11 | 0.12 | (8) | ||||||||||||||||||||||||||||||||
| Acquisition and divestiture-related costs—net of tax | — | 0.01 | * | — | 0.01 | * | ||||||||||||||||||||||||||||||||
| Certain significant items—net of tax | 0.09 | 0.12 | (25) | 0.10 | 0.14 | (29) | ||||||||||||||||||||||||||||||||
| Non-GAAP adjusted EPS—diluted | $ | 1.76 | $ | 1.56 | 13 | $ | 3.23 | $ | 2.94 | 10 | ||||||||||||||||||||||||||||
* Calculation not meaningful
(a) Diluted earnings per share was computed using the weighted-average common shares outstanding during the period plus the common stock equivalents related to stock options, restricted stock units, performance-vesting restricted stock units and deferred stock units.
Adjusted net income includes the following charges for each of the periods presented:
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||
| June 30, | June 30, | |||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||||
| Interest expense, net of capitalized interest | $ | 53 | $ | 59 | $ | 107 | $ | 117 | ||||||||||||||||||
| Interest income | 19 | 24 | 42 | 56 | ||||||||||||||||||||||
| Income taxes | 200 | 179 | 386 | 335 | ||||||||||||||||||||||
| Depreciation | 81 | 82 | 160 | 163 | ||||||||||||||||||||||
| Amortization | 9 | 10 | 17 | 18 | ||||||||||||||||||||||
32 |
Table of Contents
Adjusted net income, as shown above, excludes the following items:
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||
| June 30, | June 30, | |||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||||
| Purchase accounting adjustments: | ||||||||||||||||||||||||||
| Amortization and depreciation | $ | 33 | $ | 35 | $ | 65 | $ | 72 | ||||||||||||||||||
| Total purchase accounting adjustments—pre-tax | 33 | 35 | 65 | 72 | ||||||||||||||||||||||
Income taxes(a) | 7 | 8 | 14 | 16 | ||||||||||||||||||||||
| Total purchase accounting adjustments—net of tax | 26 | 27 | 51 | 56 | ||||||||||||||||||||||
| Acquisition and divestiture-related costs: | ||||||||||||||||||||||||||
| Acquisition-related costs | 1 | 1 | 1 | 1 | ||||||||||||||||||||||
| Divestiture-related costs | — | 4 | — | 4 | ||||||||||||||||||||||
| Total acquisition and divestiture-related costs—pre-tax | 1 | 5 | 1 | 5 | ||||||||||||||||||||||
Income taxes(a) | — | 1 | — | 1 | ||||||||||||||||||||||
| Total acquisition and divestiture-related costs—net of tax | 1 | 4 | 1 | 4 | ||||||||||||||||||||||
| Certain significant items: | ||||||||||||||||||||||||||
Other restructuring charges and cost-reduction/productivity initiatives(b) | 7 | 37 | 7 | 41 | ||||||||||||||||||||||
Business process transformation program(c) | 11 | — | 18 | — | ||||||||||||||||||||||
Certain asset impairment charges(d) | 27 | 11 | 27 | 11 | ||||||||||||||||||||||
Net loss on sale of business(e) | 3 | 22 | 3 | 22 | ||||||||||||||||||||||
| Other | (1) | — | (2) | 2 | ||||||||||||||||||||||
| Total certain significant items—pre-tax | 47 | 70 | 53 | 76 | ||||||||||||||||||||||
Income taxes(a) | 9 | 14 | 9 | 14 | ||||||||||||||||||||||
| Total certain significant items—net of tax | 38 | 56 | 44 | 62 | ||||||||||||||||||||||
| Total purchase accounting adjustments, acquisition and divestiture-related costs, and certain significant items—net of tax | $ | 65 | $ | 87 | $ | 96 | $ | 122 | ||||||||||||||||||
(a) Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction’s applicable tax rate.
(b) For the three and six months ended June 30, 2025, primarily consisted of employee termination costs related to a transition from internal to external innovation and manufacturing of certain products and the closure of a related site.
For the three and six months ended June 30, 2024, primarily consisted of employee termination costs related to organizational structure refinements. For the six months ended June 30, 2024, charges were partially offset by a reversal of certain employee termination costs as a result of a change in strategy from our 2015 operational efficiency initiative.
(c) Represents costs related to our multi-year business process transformation program, which includes the implementation of a new enterprise resource planning (ERP) system, related digital technology solutions and other related costs. This comprehensive program is a major global and cross-functional company-wide effort that we believe will transform how we work across our business and contribute to all of our strategic priorities. Due to the nature, scope and magnitude of this investment, these costs are incremental transformational costs that are far in excess of the historical normal level of spending to support operations and are not expected to recur in the foreseeable future.
(d) For the three and six months ended June 30, 2025, represents certain asset impairment charges related to a transition from internal to external innovation and manufacturing of certain products and the closure of a related site, as well as charges related to our aquaculture product portfolio.
For the three and six months ended June 30, 2024, represents certain asset impairment charges related to our aquaculture product portfolio.
(e) Represents a net loss related to the sale of our medicated feed additive product portfolio, certain water soluble products and related assets sold in 2024.
33 |
Table of Contents
The classification of the above items excluded from adjusted net income are as follows:
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||
| June 30, | June 30, | |||||||||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||||
| Cost of sales: | ||||||||||||||||||||||||||
| Purchase accounting adjustments | $ | 1 | $ | 1 | $ | 2 | $ | 2 | ||||||||||||||||||
| Business process transformation program | 2 | — | 3 | — | ||||||||||||||||||||||
| Other | (1) | — | (1) | — | ||||||||||||||||||||||
| Total Cost of sales | 2 | 1 | 4 | 2 | ||||||||||||||||||||||
| Selling, general & administrative expenses: | ||||||||||||||||||||||||||
| Purchase accounting adjustments | 3 | 3 | 6 | 6 | ||||||||||||||||||||||
| Business process transformation program | 9 | — | 15 | — | ||||||||||||||||||||||
| Total Selling, general & administrative expenses | 12 | 3 | 21 | 6 | ||||||||||||||||||||||
| Research & development expenses: | ||||||||||||||||||||||||||
| Purchase accounting adjustments | 1 | — | 1 | 1 | ||||||||||||||||||||||
| Total Research & development expenses | 1 | — | 1 | 1 | ||||||||||||||||||||||
| Amortization of intangible assets: | ||||||||||||||||||||||||||
| Purchase accounting adjustments | 28 | 31 | 56 | 63 | ||||||||||||||||||||||
| Total Amortization of intangible assets | 28 | 31 | 56 | 63 | ||||||||||||||||||||||
| Restructuring charges and certain acquisition and divestiture-related costs: | ||||||||||||||||||||||||||
| Acquisition-related costs | 1 | 1 | 1 | 1 | ||||||||||||||||||||||
| Divestiture-related costs | — | 4 | — | 4 | ||||||||||||||||||||||
| Employee termination costs | 5 | 37 | 5 | 41 | ||||||||||||||||||||||
| Asset impairments | 22 | — | 22 | — | ||||||||||||||||||||||
| Exit costs | 2 | — | 2 | — | ||||||||||||||||||||||
| Total Restructuring charges and certain acquisition and divestiture-related costs | 30 | 42 | 30 | 46 | ||||||||||||||||||||||
| Other (income)/deductions—net: | ||||||||||||||||||||||||||
| Net loss on sale of business | 3 | 22 | 3 | 22 | ||||||||||||||||||||||
| Asset impairment charges | 5 | 11 | 5 | 11 | ||||||||||||||||||||||
| Other | — | — | (1) | 2 | ||||||||||||||||||||||
| Total Other (income)/deductions—net | 8 | 33 | 7 | 35 | ||||||||||||||||||||||
| Provision for taxes on income | 16 | 23 | 23 | 31 | ||||||||||||||||||||||
| Total purchase accounting adjustments, acquisition and divestiture-related costs, and certain significant items—net of tax | $ | 65 | $ | 87 | $ | 96 | $ | 122 | ||||||||||||||||||
Analysis of the condensed consolidated statements of comprehensive income
Changes in other comprehensive income for the periods presented are primarily related to foreign currency translation adjustments and unrealized gains/(losses) on derivative instruments. The foreign currency translation adjustment changes result from the strengthening or weakening of the U.S. dollar as compared to the currencies in the countries in which we do business. Unrealized gains/(losses) on the changes in the fair value of derivative instruments are recorded within Accumulated other comprehensive income/(loss) and reclassified into earnings depending on the nature and purpose of the financial instrument, as described in Note 9. Financial Instruments of the Notes to Condensed Consolidated Financial Statements.
Analysis of the condensed consolidated balance sheets
June 30, 2025 vs. December 31, 2024
For a discussion about the changes in Cash and cash equivalents, Short-term borrowings and Long-term debt, net of discount and issuance costs, see “Analysis of financial condition, liquidity and capital resources” below.
Accounts receivable, less allowance for doubtful accounts increased primarily as a result of higher net sales in the period.
Inventories increased as a result of inventory build-up to support production for the forecasted demand of certain products.
Other current assets increased primarily due to the timing of income taxes paid and the jurisdictional netting of income taxes receivable and income taxes payable, as well as an increase in collateral posted related to derivative contracts, partially offset by the mark-to-market adjustments of derivative instruments.
34 |
Table of Contents
The increase in Operating lease right-of-use assets reflects assets acquired through new and amended lease agreements, partially offset by lease amortization, while the increase in Operating lease liabilities primarily reflects an amended lease obligation in the current period, partially offset by lease payments.
The net changes in Noncurrent deferred tax assets, Noncurrent deferred tax liabilities, Income taxes payable and Other taxes payable primarily reflect adjustments to the accrual for the income tax provision, the timing of income tax payments and the tax impact of various acquisitions.
Other noncurrent assets increased primarily due to capitalized cloud computing arrangements implementation costs, partially offset by the mark-to-market adjustments of derivative instruments.
Accounts payable increased as a result of the timing of vendor and value-added tax payments.
Accrued compensation and related items decreased primarily due to the payments of 2024 annual incentive bonuses, savings plan contributions to eligible employees and payments for sales incentive bonuses, partially offset by the accrual of 2025 annual incentive bonuses, sales incentive bonuses and savings plan contributions to eligible employees.
Other noncurrent liabilities increased primarily due to the mark-to-market adjustments of derivative instruments.
For an analysis of the changes in Total Equity, see the Condensed Consolidated Statements of Equity and Notes to Condensed Consolidated Financial Statements— Note 13. Stockholders’ Equity.
Analysis of the condensed consolidated statements of cash flows
| Six Months Ended | ||||||||||||||||||||
| June 30, | $ | |||||||||||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | Change | |||||||||||||||||
| Net cash provided by (used in): | ||||||||||||||||||||
Operating activities | $ | 1,073 | $ | 1,097 | $ | (24) | ||||||||||||||
Investing activities | (422) | (263) | (159) | |||||||||||||||||
Financing activities | (1,241) | (1,287) | 46 | |||||||||||||||||
| Effect of exchange-rate changes on cash and cash equivalents | 38 | (14) | 52 | |||||||||||||||||
| Net decrease in cash and cash equivalents | $ | (552) | $ | (467) | $ | (85) | ||||||||||||||
Operating activities
Six months ended June 30, 2025 vs. six months ended June 30, 2024
Net cash provided by operating activities was $1,073 million for the six months ended June 30, 2025, compared with $1,097 million for the six months ended June 30, 2024. The decrease in operating cash flows was primarily attributable to the timing of income taxes paid, the timing of receipts and payments in the ordinary course of business and higher inventory build-up of certain products due to increased demand, partially offset by higher net income adjusted by non-cash items.
Investing activities
Six months ended June 30, 2025 vs. six months ended June 30, 2024
Our net cash used in investing activities was $422 million for the six months ended June 30, 2025, compared with net cash used in investing activities of $263 million for the six months ended June 30, 2024. The net cash used in investing activities for the six months ended June 30, 2025 was primarily due to capital expenditures and net payments of derivative instrument activity. The net cash used in investing activities for the six months ended June 30, 2024 was primarily due to capital expenditures, partially offset by net proceeds from derivative instrument activity.
Financing activities
Six months ended June 30, 2025 vs. six months ended June 30, 2024
Our net cash used in financing activities was $1,241 million for the six months ended June 30, 2025, compared with net cash used in financing activities of $1,287 million for the six months ended June 30, 2024. The net cash used in financing activities for the six months ended June 30, 2025 and 2024 was primarily attributable to the purchase of treasury shares, the payment of dividends and taxes paid on withholding shares, partially offset by proceeds in connection with the issuance of common stock under our equity incentive plan.
Analysis of financial condition, liquidity and capital resources
While we believe our cash and cash equivalents on hand, our operating cash flows and our existing financing arrangements will be sufficient to support our cash needs for the next twelve months and beyond, this may be subject to the environment in which we operate. Risks to our meeting future funding requirements are described in Global economic conditions below.
35 |
Table of Contents
Selected measures of liquidity and capital resources
Certain relevant measures of our liquidity and capital resources follow:
| June 30, | December 31, | ||||||||||
| (MILLIONS OF DOLLARS) | 2025 | 2024 | |||||||||
| Cash and cash equivalents | $ | 1,435 | $ | 1,987 | |||||||
Accounts receivable, net(a) | 1,540 | 1,316 | |||||||||
| Current portion of long-term debt | 1,350 | 1,350 | |||||||||
| Long-term debt | 5,231 | 5,220 | |||||||||
| Working capital | 2,557 | 2,574 | |||||||||
| Ratio of current assets to current liabilities | 1.76:1 | 1.75:1 | |||||||||
(a) Accounts receivable are usually collected over a period of 45 to 75 days. For the six months ended June 30, 2025 and December 31, 2024, the number of days that accounts receivables were outstanding remained within this range. We regularly monitor our accounts receivable for collectability, particularly in markets where economic conditions remain uncertain. We believe that our allowance for doubtful accounts is appropriate. Our assessment is based on such factors as past due aging, historical and expected collection patterns, the financial condition of our customers, the robust nature of our credit and collection practices and the economic environment.
For additional information about the sources and uses of our funds, see the Analysis of the condensed consolidated balance sheets and Analysis of the condensed consolidated statements of cash flows sections of this MD&A.
Credit facility and other lines of credit
In December 2022, we entered into an amended and restated revolving credit agreement with a syndicate of banks providing for a multi-year $1.0 billion senior unsecured revolving credit facility (the credit facility), which expires in December 2027. Subject to certain conditions, we have the right to increase the credit facility to up to $1.5 billion. The credit facility contains a financial covenant requiring us to not exceed a maximum total leverage ratio (the ratio of consolidated net debt as of the end of the period to consolidated Earnings Before Interest, Income Taxes, Depreciation and Amortization (EBITDA) for such period) of 3.50:1. Upon entering into a material acquisition, the maximum total leverage ratio increases to 4.00:1, and extends until the fourth full consecutive fiscal quarter ended immediately following the consummation of a material acquisition. In addition, the credit facility contains other customary covenants.
We were in compliance with all financial covenants as of June 30, 2025 and December 31, 2024. There were no amounts drawn under the credit facility as of June 30, 2025 or December 31, 2024.
We have additional lines of credit and other credit arrangements with a group of banks and other financial intermediaries for general corporate purposes. We maintain cash and cash equivalent balances in excess of our outstanding short-term borrowings. As of June 30, 2025, we had access to $53 million of lines of credit which expire at various times and are generally renewed annually. There were no borrowings outstanding related to these facilities as of June 30, 2025 and December 31, 2024.
Domestic and international short-term funds
Many of our operations are conducted outside the U.S. The amount of funds held in the U.S. will fluctuate due to the timing of receipts and payments in the ordinary course of business and due to other reasons, such as business development activities. As part of our ongoing liquidity assessments, we regularly monitor the mix of U.S. and international cash flows (both inflows and outflows). Actual repatriation of overseas funds can result in additional U.S. and local income taxes, such as U.S. state income taxes, local withholding taxes, and taxes on currency gains and losses.
Global economic conditions
Global financial markets may be impacted by macroeconomic, business and financial volatility. Challenging economic conditions in recent years have not had, nor do we anticipate that it will have, a significant impact on our liquidity. Due to our operating cash flows, financial assets, access to capital markets and available lines of credit and revolving credit agreements, we continue to believe that we have the ability to meet our liquidity needs for the foreseeable future. As markets change, we continue to monitor our liquidity position. There can be no assurance that a challenging economic environment or an economic downturn will not impact our liquidity or our ability to obtain financing in the future.
Debt securities
Our senior notes are governed by an indenture and supplemental indentures (collectively, the indenture) between us and Deutsche Bank Trust Company Americas, as trustee. The indenture contains certain covenants, including limitations on our and certain of our subsidiaries’ ability to incur liens or engage in sale lease-back transactions. The indenture also contains restrictions on our ability to consolidate, merge or sell substantially all of our assets. In addition, the indenture contains other customary terms, including certain events of default, upon the occurrence of which, the senior notes may be declared immediately due and payable.
Pursuant to the indenture, we are able to redeem the senior notes of any series, in whole or in part, at any time by paying a “make whole” premium, plus accrued and unpaid interest to, but excluding, the date of redemption. Upon the occurrence of a change of control of us and a downgrade of the senior notes below an investment grade rating by each of Moody’s Investors Service, Inc. and Standard & Poor’s Ratings Services, we are, in certain circumstances, required to make an offer to repurchase all of the outstanding senior notes at a price equal to 101% of the aggregate principal amount of the senior notes together with accrued and unpaid interest to, but excluding, the date of repurchase.
36 |
Table of Contents
Our outstanding debt securities are as follows:
| Description | Principal Amount | Interest Rate | Terms | ||||||||
| 2015 Senior Notes due 2025 | $750 million | 4.500% | Interest due semi annually, not subject to amortization, aggregate principal due on November 13, 2025 | ||||||||
| 2022 Senior Notes due 2025 | $600 million | 5.400% | Interest due semi annually, not subject to amortization, aggregate principal due on November 14, 2025 | ||||||||
| 2017 Senior Notes due 2027 | $750 million | 3.000% | Interest due semi annually, not subject to amortization, aggregate principal due on September 12, 2027 | ||||||||
| 2018 Senior Notes due 2028 | $500 million | 3.900% | Interest due semi annually, not subject to amortization, aggregate principal due on August 20, 2028 | ||||||||
| 2020 Senior Notes due 2030 | $750 million | 2.000% | Interest due semi annually, not subject to amortization, aggregate principal due on May 15, 2030 | ||||||||
| 2022 Senior Notes due 2032 | $750 million | 5.600% | Interest due semi annually, not subject to amortization, aggregate principal due on November 16, 2032 | ||||||||
| 2013 Senior Notes due 2043 | $1,150 million | 4.700% | Interest due semi annually, not subject to amortization, aggregate principal due on February 1, 2043 | ||||||||
| 2017 Senior Notes due 2047 | $500 million | 3.950% | Interest due semi annually, not subject to amortization, aggregate principal due on September 12, 2047 | ||||||||
| 2018 Senior Notes due 2048 | $400 million | 4.450% | Interest due semi annually, not subject to amortization, aggregate principal due on August 20, 2048 | ||||||||
| 2020 Senior Notes due 2050 | $500 million | 3.000% | Interest due semi annually, not subject to amortization, aggregate principal due on May 15, 2050 | ||||||||
Credit ratings
Two major corporate debt-rating organizations, Moody’s and S&P, assign ratings to our short-term and long-term debt. A security rating is not a recommendation to buy, sell or hold securities and the rating is subject to revision or withdrawal at any time by the rating organization. Each rating should be evaluated independently of any other rating.
The following table provides the current ratings assigned by these rating agencies to our commercial paper and senior unsecured non-credit-enhanced long-term debt:
| Commercial Paper | Long-term Debt | Date of Last Action | ||||||||||||||||||||||||
| Name of Rating Agency | Rating | Rating | Outlook | |||||||||||||||||||||||
| Moody’s | P-2 | A3 | Stable | January 2025 | ||||||||||||||||||||||
| S&P | A-2 | BBB+ | Stable | April 2025 | ||||||||||||||||||||||
Share repurchase program
In August 2024, our Board of Directors authorized a multi-year share repurchase program of up to $6 billion of our outstanding common stock. As of June 30, 2025, there was $4.9 billion remaining under this authorization. Purchases of Zoetis shares may be made at the discretion of management, depending on market conditions and business needs. Share repurchases may be executed through various means, including open market or privately negotiated transactions. During the first six months of 2025, 4.8 million shares were repurchased for $781 million, which excludes a $7 million accrual for excise tax on net share repurchases.
Off-balance sheet arrangements
In the ordinary course of business and in connection with the sale of assets and businesses, we may indemnify our counterparties against certain liabilities that may arise in connection with a transaction or that are related to activities prior to a transaction. These indemnifications typically pertain to environmental, tax, employee and/or product-related matters, and patent-infringement claims. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications are generally subject to threshold amounts, specified claim periods and other restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of June 30, 2025 and December 31, 2024, recorded amounts for the estimated fair value of these indemnifications are not material.
New accounting standards
See Note 3. Significant Accounting Policies in the Notes to Condensed Consolidated Financial Statements for discussion of recent accounting pronouncements, including the respective dates of adoption or expected adoption and effects or expected effects on our consolidated financial position, results of operations and cash flows.
Forward-looking statements and factors that may affect future results
This report contains “forward-looking” statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. We generally identify forward-looking statements by using words such as “anticipate,” “estimate,” “could,” “expect,” “intend,” “project,” “plan,” “predict,” “believe,” “seek,” “continue,” “outlook,” "forecast,” “objective,” “target,” “may,” “might,” “will,” “should,” “can have,” “likely” or the negative version of these words or comparable words or by using future dates in connection with any discussion of future performance, actions or events.
In particular, forward-looking statements include statements relating to our future actions, business plans or prospects, prospective products, product approvals or products under development, product and supply chain disruption, R&D costs, timing and likelihood of success, future operating or financial performance, future results of current and anticipated products and services, product strategies, sales efforts, expenses, production efficiencies, production margins, anticipated timing of generic market entries, integration of acquired businesses, anticipated impact of timing of divestitures, interest rates, tax rates, tariffs, changes in tax regimes and laws, foreign exchange rates, growth in emerging markets, the outcome of contingencies, such as legal proceedings, plans related to share repurchases and dividends, government regulation, taxes and financial results. These statements are not guarantees of future performance, actions or events. Forward-looking statements are subject to risks and uncertainties, many of which are beyond our control, and are based on assumptions that could prove to be inaccurate. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following:
37 |
Table of Contents
•the possible impact and timing of competing products, including generic alternatives, on our products and our ability to compete against such products;
•unanticipated safety, quality or efficacy concerns or issues about our products;
•the economic, political, legal and business environment of the foreign jurisdictions in which we do business;
•the decline in global economic conditions, economic weakness in China and inflation;
•consolidation of our customers and distributors;
•changes in the distribution channel for companion animal products;
•an outbreak of infectious disease carried by animals;
•disruptive innovations and advances in medical practices and technologies;
•failure to successfully acquire businesses, license rights or products, integrate businesses, form and manage alliances or divest businesses;
•restrictions and bans on the use of and consumer preferences regarding antibacterials in food-producing animals;
•perceived adverse effects linked to the consumption of food derived from animals that utilize our products or animals generally;
•increased regulation or decreased governmental support relating to the raising, processing or consumption of food-producing animals;
•modification of foreign trade policy by the U.S. or other countries, including the imposition of increased tariffs on imported or exported goods;
•adverse weather conditions and the availability of natural resources;
•the impact of climate change on our activities and the activities of our customers and suppliers;
•an inability to hire and retain executive officers and other key personnel;
•product launch delays, inventory shortages, recalls or unanticipated costs caused by manufacturing problems and capacity imbalances;
•availability constraints and price volatility caused by changes in supply conditions, government regulations, tariffs, economic climate and other factors, including with products, materials and services provided to us by third parties;
•failure of our R&D, acquisition and licensing efforts to generate new products and product lifecycle innovations;
•difficulties or delays in the development or commercialization of new products;
•illegal distribution and/or sale of our products or the misuse or off-label use of our products;
•legal factors, including product liability claims, antitrust litigation and governmental investigations, including tax disputes, environmental concerns, laws and regulations regarding data privacy, commercial disputes and patent disputes with branded and generic competitors, any of which could preclude commercialization of products or negatively affect the profitability of existing products;
•fluctuations in foreign exchange rates and potential currency controls;
•a cyberattack, information security breach or other misappropriation of our data;
•governmental laws and regulations affecting domestic and foreign operations, including without limitation, delays in the United States resulting from federal workforce reductions or hiring freezes, federal agency reorganizations or deregulatory efforts, or existing, new and proposed tax laws and regulations affecting the U.S. or foreign taxation of our business activities, including the imposition of, or increase in, taxes based on gross revenues;
•failure to protect our intellectual property rights or to operate our business without infringing the intellectual property rights of others;
•failure to generate sufficient cash to service our substantial indebtedness; and
•the other factors set forth under “Risk Factors” in Item 1A. of Part I of our 2024 Annual Report on Form 10-K and Item 1A. of Part II in this Form 10-Q.
However, there may also be other risks that we are unable to predict at this time. These risks or uncertainties may cause actual results to differ materially from those contemplated by a forward-looking statement. You should not put undue reliance on forward-looking statements. Forward-looking statements speak only as of the date on which they are made. We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law or by the rules and regulations of the SEC. You are advised, however, to consult any further disclosures we make on related subjects in our Form 10-Q and 8-K reports and our other filings with the SEC. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider the above to be a complete discussion of all potential risks or uncertainties.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
A significant portion of our revenue and costs are exposed to changes in foreign exchange rates. In addition, our outstanding borrowings may be subject to risk from changes in interest rates and foreign exchange rates. The overall objective of our financial risk management program is to seek to manage the impact of foreign exchange rate movements and interest rate movements on our earnings. We manage these financial exposures through operational means and by using certain financial instruments. These practices may change as economic conditions change.
For a complete discussion of our exposure to interest rate and foreign exchange risk, refer to Item 7A. Quantitative and Qualitative Disclosures About Market Risk in our Annual Report on Form 10-K for the year ended December 31, 2024. There have been no material changes from the information discussed therein.
38 |
Table of Contents
Item 4. Controls and Procedures
Disclosure Controls and Procedures
An evaluation was carried out under the supervision and with the participation of the company’s management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934). Based upon that evaluation as of June 30, 2025, the company’s Chief Executive Officer and Chief Financial Officer concluded that the company’s disclosure controls and procedures are effective at a reasonable level of assurance in alerting them in a timely manner to material information required to be disclosed in our periodic reports filed with the SEC.
Changes in Internal Control over Financial Reporting
During our most recent fiscal quarter, there has not been any change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
39 |
Table of Contents
PART II — OTHER INFORMATION
Item 1. Legal Proceedings
The information required by this Item is incorporated herein by reference to Notes to Condensed Consolidated Financial Statements—Note 15. Commitments and Contingencies in Part I— Item 1, of this Quarterly Report on Form 10-Q.
Item 1A. Risk Factors
In addition to the other information set forth in this Form 10-Q, you should carefully consider the factors discussed in the "Our operating environment" and "Forward-looking statements and factors that may affect future results" sections of the MD&A and in Part I, Item 1A. "Risk Factors," of our 2024 Annual Report on Form 10-K, which could materially affect our business, financial condition, or future results and which are incorporated by reference herein. Set forth below are updates to certain of the risk factors disclosed in our 2024 Annual Report on Form 10-K.
Risks related to our business and the animal health industry
Modification of foreign trade policy by the U.S. or other countries or the imposition of tariffs on imported goods may harm our business.
The U.S. and other countries in which our products are sourced or sold, or we or our customers do business, may from time to time modify existing or impose new quotas, duties (including antidumping or countervailing duties), tariffs or other restrictions in a manner that adversely affects us. For example, the recent announcements of substantial new tariffs and other restrictive trade policies have created a dynamic and unpredictable trade landscape.
Current or future tariffs or other restrictive trade measures may raise the costs of raw materials, components or finished goods, which may adversely impact both our product offerings and our operational expenses. Our manufacturers, suppliers and distribution channels are also affected by the current trade environment, and we may experience supply chain disruptions as a result of increased costs and uncertainty. Tariff and other trade-related cost pressures and supply chain disruptions may lead to reputational harm if we are unable to deliver products or services on expected timelines or if any price increases are poorly received by customers or business partners.
Additional tariffs on imports could result in a negative perception and/or an increased cost of goods and higher prices which may reduce customer demand for products, or extended sales cycles as customers assess the impact of evolving trade policies on their operations and face increased costs or decreased revenue due to tariffs and trade restrictions. Additionally, a number of our customers, particularly U.S.-based livestock producers, benefit from free trade agreements, the loss of which could impact their operating results and spending power.
In addition, retaliatory trade policies or anti-U.S. sentiment in certain regions whether driven by trade tensions, political disagreements or regulatory concerns may make customers, governments and investors more hesitant to engage with, purchase from or invest in U.S. companies. This may lead to increased preference for local competitors, changes to government procurement policies or heightened regulatory scrutiny, which may result in heightened operational risks and difficulties for us in attracting and retaining non-U.S. customers, suppliers, partners and investors.
While the scope and duration of any tariffs remains uncertain, tariffs imposed by the U.S. or other governments on our products or the active pharmaceutical ingredients or other components thereof could negatively impact our financial condition and results of operations.
Risks related to manufacturing and supply
We rely on third parties to provide us with products, materials and services, and are subject to increased labor and material costs and potential disruptions in supply.
The materials used to manufacture our products may be subject to availability constraints and price volatility caused by changes in demand, weather conditions, supply conditions, government regulations, tariffs, economic climate and other factors. In addition, labor costs may be subject to volatility caused by the supply of labor, governmental regulations, tariffs, economic climate and other factors. Increases in the demand for, availability or the price of, materials used to manufacture our products and increases in labor costs could increase the costs to manufacture our products, result in product delivery delays or shortages, and impact our ability to launch new products on a timely basis or at all. We may not be able to pass all or a material portion of any higher product, material, transportation or labor costs on to our customers, which could materially adversely affect our operating results and financial condition.
Certain third-party suppliers are the sole or exclusive source of certain products, materials and services necessary for production of our products. We may be unable to meet demand for certain of our products if any of our third-party suppliers cease or interrupt operations due to, among other things, escalating tensions or trade disputes in their region, restrictions on the import/export of goods or services, contract manufacturing or supply chain disruptions due to contract manufacturer or supplier financial distress, our failure to mutually renew contract terms, or some other failure of a contractor or supplier to meet their obligations to us. In such a case, we may be required to renegotiate the terms of our agreement or pursue a strategic transaction or other alternative arrangement with that supplier or others.
Risks related to legal matters and regulation
Our business is subject to substantial regulation.
As a global company, we are subject to various state, federal and international laws and regulations, including regulations relating to the research, development, quality assurance, manufacturing, importation, exportation, distribution, marketing and sale of our products, including our in vitro diagnostic products used in human health. In addition, our manufacturing facilities are subject to periodic inspections by regulatory agencies, such as the FDA, the USDA and foreign equivalents. Our failure, or the failure of third parties we rely on, including CMOs, to comply with these regulatory requirements, allegations of such non-compliance or the discovery of previously unknown problems with a product or manufacturer could result in, among other things, inspectional observation notices, label changes, untitled or warning letters or other public regulatory communications or correspondence, fines, a partial or total shutdown of production in one or more of our facilities while an alleged violation is remediated, withdrawals or suspensions of current products from the market, product seizures, injunctions and civil or criminal prosecution, as well as decreased sales as a
40 |
Table of Contents
result of negative publicity and product liability claims. Any one of these consequences could materially adversely affect our operating results and financial condition.
In addition, we will not be able to market new products unless and until we have obtained all required regulatory approvals in each jurisdiction where we propose to market those products. Even after a product reaches market, it may be subject to re-review and may lose its approvals. We have changed, and may in the future change, the locations of where certain of our products are manufactured and, because of these changes, we may be required to obtain new regulatory approvals. Our failure to obtain approvals, delays in the approval process, including any delays in the United States resulting from federal workforce reductions or hiring freezes, federal agency reorganizations or deregulatory efforts, or any prolonged shutdown of the U.S. government, or our failure to maintain approvals in any jurisdiction, may prevent us from selling products in that jurisdiction until approval or reapproval is obtained, if ever.
The OFAC at the U.S. Treasury Department and the Bureau of Industry and Security at the U.S. Department of Commerce (BIS), and similar agencies in other countries and territories outside the U.S., administer certain laws and regulations that restrict its persons and, in some instances, extraterritorial persons, in conducting activities, transacting business with or making investments in certain countries, governments, entities and individuals subject to economic sanctions. Our international operations subject us to these laws and regulations, which are complex, restrict our business dealings with certain countries, governments, entities, and individuals, and are constantly changing. For example, we sell limited humanitarian animal health products, including medicines, diagnostics and vaccines, to Russia and Iran, in compliance with economic sanctions affecting these countries. Violations of sanctions regulations may be punishable by civil penalties, including fines, denial of export privileges, injunctions, asset seizures, debarment from government contracts and revocations or restrictions of licenses, as well as criminal fines and imprisonment, which could adversely affect our reputation, business, financial condition, results of operations and cash flows. In addition, our internal control policies and procedures may not protect us from reckless or criminal acts committed by our employees and agents. For example, in December 2020, we submitted a final voluntary disclosure to OFAC and the U.S. Department of Justice regarding certain transactions involving sales of food, medicine or devices to individuals or entities who may have been resident in or had ties to Iran potentially in violation of the ITSR administered by OFAC. The sales were made by our Platinum Performance business, which we acquired in August 2019. In July 2023, OFAC provided a No Action letter confirming a final determination that no further action would be taken in the matter. We do not anticipate further communication from the Department of Justice as the statutory response period has lapsed without a response.
A failure to comply with the environmental, health and safety laws and regulations to which we are subject, including any permits issued thereunder, may result in environmental remediation costs, loss of permits, public regulatory communications or announcements, fines, penalties or other adverse governmental or private actions, including regulatory or judicial orders enjoining or curtailing operations or requiring corrective measures, installation of pollution control equipment or remedial measures. We cannot assure you that our costs of complying with current and future environmental, health and safety laws, and our liabilities arising from past or future releases of, or exposure to, hazardous materials will not materially adversely affect our business, results of operations or financial condition.
There has been a broad range of proposed and promulgated state, national and international regulation aimed at reducing the effects of climate change. Such regulations apply or could apply in countries where we have interests or could have interests in the future. The EU adopted the European Sustainability Reporting Standards (ESRS) and the Corporate Sustainability Reporting Directive (CSRD) that will require disclosure by EU entities, including certain EU subsidiaries of non-EU entities, regarding the risks and opportunities arising from environmental, social and corporate governance issues, and on the impact of companies' activities on people and the environment. Similarly, the State of California passed the Climate Corporate Data Accountability Act and the Climate-Related Financial Risk Act that imposes broad climate-related disclosure obligations on certain companies doing business in California, including us. Any new regulation could take several forms that could result in additional costs in the form of investments of capital to maintain compliance with laws and regulations and taxes. Climate change regulation continues to evolve, and it is not possible to accurately estimate either a timetable for implementation or our future compliance costs relating to implementation.
We are also subject to chemical regulation in the United States and internationally. For example, governmental authorities in the EU and the United States are increasingly focused on preventing environmental contamination from per- and polyfluoroalkyl substances (PFAS), which may be contained in certain of our products or product packaging. Federal and state governments and regulatory agencies, like the European Chemicals Agency, are in various stages of considering and/or implementing laws and regulations requiring the reporting, restriction and/or phase-out of PFAS-containing products (subject to applicable product exceptions).
Furthermore, we cannot predict the nature of future laws, regulations, or changes in tax laws and tariffs, nor can we determine the effect that additional laws or regulations or changes in existing laws or regulations could have on our business when and if promulgated. Changes in applicable federal, state, local and foreign laws and regulations could have a material adverse effect on our operating results and financial condition.
41 |
Table of Contents
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
In August 2024, our Board of Directors authorized a multi-year share repurchase program of up to $6 billion of our outstanding common stock. As of June 30, 2025, there was $4.9 billion remaining under this program.
The following table provides information with respect to the shares of the company’s common stock repurchased during the three months ended
June 30, 2025:
Issuer Purchases of Equity Securities(a) | |||||||||||||||||||||||
Total Number of Shares Purchased(b) | Average Price Paid Per Share | Total Number of Shares Purchased as Part of Publicly Announced Programs | Approximate Dollar Value of Shares that May Yet Be Purchased Under Plans or Programs | ||||||||||||||||||||
| April 1 - April 30, 2025 | 813,748 | $151.49 | 812,772 | $5,080,779,779 | |||||||||||||||||||
| May 1 - May 31, 2025 | 537,006 | $158.86 | 536,803 | $4,995,501,564 | |||||||||||||||||||
| June 1 - June 30, 2025 | 790,407 | $162.72 | 790,031 | $4,866,452,211 | |||||||||||||||||||
| 2,141,161 | $157.48 | 2,139,606 | $4,866,452,211 | ||||||||||||||||||||
(a) Amounts exclude the impact of excise tax on net share repurchases.
(b) The company repurchased 1,555 shares during the three-month period ended June 30, 2025 that were not part of the publicly announced multi-year share repurchase authorization. These shares were reacquired from employees to satisfy tax withholding requirements on the vesting of restricted shares from equity-based awards.
Item 3. Defaults Upon Senior Securities
None
Item 4. Mine Safety Disclosures
None
Item 5. Other Information
We are reporting the following information in lieu of reporting on a Current Report on Form 8-K under Item 5.02 Compensatory Arrangements of Certain Officers.
Following a periodic review of market terms, on July 31, 2025, the Zoetis Inc. (the “Company”) Board of Directors approved an amendment and restatement of the Zoetis Executive Severance Plan (the “Plan”), in which each of the Company’s named executive officers is a participant. Upon a qualifying termination absent a “change of control,” the material changes to the Plan include increases to the number of months of base salary severance, the multiple applied to the participant’s target bonus to determine the amount of target bonus severance and the number of months of Company-paid health and life insurance benefits provided to the participant. Upon a qualifying termination that occurs on or within 24 months of a “change of control,” the material changes to the Plan include increases to the number of months of Company-paid health and life insurance coverage provided to the participant and the addition of a pro-rata annual bonus for the year of termination based on the target bonus pro-rated for the length of service and through the date of termination. The Plan also provides for a new “better-net” cutback that provides that any payments and benefits under the Plan will be reduced to the extent that they would be subject to an excise tax under Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, unless the executive officer would be better off on an after-tax basis receiving all such payments and benefits and paying his or her own excise tax.
The foregoing description of the Plan is qualified in its entirety by reference to the full text of the Plan, which is filed herewith as Exhibit 10.1.
42 |
Table of Contents
Item 6. Exhibits
Exhibit 10.1 | Zoetis Executive Severance Plan, as amended and restated effective July 31, 2025 * | |||||||
Exhibit 31.1 | Chief Executive Officer–Certification pursuant to Sarbanes-Oxley Act of 2002 Section 302 | |||||||
Exhibit 31.2 | Chief Financial Officer–Certification pursuant to Sarbanes-Oxley Act of 2002 Section 302 | |||||||
Exhibit 32.1 | Chief Executive Officer–Certification pursuant to Sarbanes-Oxley Act of 2002 Section 906 | |||||||
Exhibit 32.2 | Chief Financial Officer–Certification pursuant to Sarbanes-Oxley Act of 2002 Section 906 | |||||||
| EX-101.INS | Inline XBRL INSTANCE DOCUMENT | |||||||
EX-101.SCH | Inline XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT | |||||||
EX-101.CAL | Inline XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT | |||||||
EX-101.LAB | Inline XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT | |||||||
EX-101.PRE | Inline XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT | |||||||
EX-101.DEF | Inline XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT | |||||||
| EX-104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | |||||||
| * | Management contracts or compensatory plans or arrangements | ||||
43 |
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Zoetis Inc. | ||||||||
| August 5, 2025 | By: | /S/ KRISTIN C. PECK | ||||||
Kristin C. Peck | ||||||||
Chief Executive Officer and Director | ||||||||
| August 5, 2025 | By: | /S/ WETTENY JOSEPH | ||||||
| Wetteny Joseph | ||||||||
| Executive Vice President and Chief Financial Officer | ||||||||
44 |
FAQ
How much did Zoetis (ZTS) earn per share in Q2 2025?
Diluted EPS rose to $1.61, up 17.5% from $1.37 in Q2 2024.
What drove Zoetis' revenue growth in the quarter?
Growth was led by companion animal products—parasiticides (+12%), vaccines (+13%), dermatology (+11%).
Why did cash decline despite higher earnings?
Zoetis spent $781 m on share buybacks and paid $447 m in dividends, exceeding operating cash inflow.
How is the livestock segment performing?
Livestock revenue dropped 8.1% YoY to $638 m, hurt by cattle (-8.6%) and poultry (-22%).
What is the status of the $6 bn share repurchase program?
After buying back $788 m YTD 2025, $4.9 bn remains authorized.
Are there any major legal or tax contingencies?
Yes. An IRS audit could impose an additional tax of about $450 m, though Zoetis disputes the claim.
Zoetis Inc
NYSE:ZTS
ZTS Rankings
ZTS Latest News
May 21, 2025
Zoetis Declares Third Quarter 2025 Dividend
ZTS Latest SEC Filings
Aug 5, 2025
[S-3ASR] ZOETIS INC. SEC Filing
Aug 5, 2025
[8-K] ZOETIS INC. Reports Material Event
Jul 28, 2025
[Form 4] ZOETIS INC. Insider Trading Activity
Jul 15, 2025
[Form 4] ZOETIS INC. Insider Trading Activity
Jul 15, 2025
[Form 4] ZOETIS INC. Insider Trading Activity
ZTS Stock Data
65.05B
444.19M
0.23%
96.75%
1.76%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
United States
PARSIPPANY